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1
Outline of the thesis
Diabetes mellitus is a group of metabolic diseases characterized by persistent hyper-
glycemia. The prevalence of diabetes is 415 million worldwide and the numbers are 
on the rise [1]. The underlying mechanisms of diabetes are auto-immune destruction 
of the insulin producing cells (у-cells), which is characteristic for type 1 diabetes, or 
insufﬁcient insulin secretion due to insulin resistance, which is – together with other 
factors – typical for type 2 diabetes.
The most common approach to maintain blood glucose level within the
physiological range (90-110 mg/dl, or 4-6 mmol/L) in T1D patients is to receive insulin
injections on a daily basis. This approach is however associated with several dis-
advantages, such as regular episodes of hypoglycemia, potentially overall poor 
blood glucose control with the risk of developing long-term diabetes complications 
(such as blindness, cardiovascular disease, kidney failure etc.); alternative methods 
are therefore required.
Since the establishment of the Edmonton protocol by Chapiro et al. [2], pancreatic 
islet transplantation has become a promising experimental option for treating type 1 
diabetes patients, where transplanted islets compensate for the у-cell loss in the
pancreas, signiﬁcantly reducing the necessity for insulin injections and reducing the 
rate of hypoglycemic episodes [3]. However, most subjects are reverted to using 
insulin 5 years after transplantation [4]. The leading causes of relapse are the poor 
rate of islet engraftment, hypoxia, gluco/lipotoxicity, auto-immunity and immuno-
suppression toxicity, all resulting in decline in islet survival and function [5, 6].
Intensive research was conducted during the past decades for improving the 
clinical outcome of islet transplantation, not only by elucidating the pathways that 
lead to у-cell loss and dysfunction, but also by understanding how the decrease in 
у-cell number, or у-cell mass (BCM), is linked to progressive relapse into hyper-
glycemia. Indeed, the relationship between BCM and their ability in maintaining 
normoglycemia (or function) is unclear, and the players that cause the discrepancy 
between BCM and function are multifactorial [7, 8].
To date, it remains difﬁcult to quantify islet survival given that clinical functional 
tests cannot discriminate between BCM and function (BCF). A reliable non-invasive
method is therefore needed to monitor graft survival, independently of its function. 
Such method should provide information regarding the number of surviving islets, 
and the technique should be applied repeatedly and non-invasively with regard to
clinical implementation.
Radioactive-based imaging modalities (SPECT: Single Photon Emission Computed 
Tomography; PET: Positron Emission Tomography) are attractive technologies for 
non-invasive imaging of the у-cells after injection of у-cell speciﬁc radiotracers [9-11]. 
These techniques offer high sensitivity, prompting the detection of very small 
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Chapter 1
differences in BCM. One promising tracer for у-cell imaging is radiolabeled exendin,
which speciﬁcally accumulates in the у-cells after binding to the GLP-1R expressed
on their surface. The utility of this radiotracer for imaging of islet transplants was 
demonstrated in a mouse model for islet transplantation where у-cells were visualized
by PET after injection of Cu-64 or F-18 labeled exendin-4 and in a clinical case study
where у-cells were visualized by SPECT after injection of 111In-labeled exendin-4 [12, 13].
The main focus of this thesis is to determine the possibility to quantify BCM of 
islets transplanted in the skeletal muscle by SPECT in healthy (control model) and 
type 1 diabetic mice, using 111In-exendin-3. In Chapter 1, an overview is provided 
about the current state-of-the-art in radionuclide imaging of islet grafts and the use of
small animal models for characterizing novel у-cell radiotracers. In Chapter 2, the 
role of islet graft revascularization for in vivo delivery of 111In-exendin to the islets was 
determined by follow-up of 111In-exendin-3 accumulation by the islets during the ﬁrst
weeks after transplantation. In this Chapter, we determined the optimal time-point after 
which reproducible (quantitative) imaging of islet grafts can be achieved. In Chapter 3, 
we studied the correlation between exendin accumulation and the BCM in transplants 
containing various amounts of islets (50 to 800 islets). In Chapter 4, we evaluated the 
possibility for in vivo monitoring of islet transplants in diabetic recipients where islet
grafts underwent severe hyperglycemic stress. Finally, we described in Chapter 5
a multi-modal imaging approach for fast and reliable cross-examination of 111In-exendin
performances in BCM assessment.
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1.  Role of imaging in islet transplantation
Diabetes mellitus is a group of metabolic disorders characterized by long-standing
hyperglycemia. In type 1 diabetes (T1D), the inability in maintaining normoglycemia 
results from auto-immune destruction of the у-cells and consequently, insulin-
dependency. In type 2 diabetes (T2D), hyperglycemia results from resistance to 
insulin by the hormone target cells (namely myocytes and adipocytes) in association 
with insufﬁcient insulin secretory response.
The auto-immune form of diabetes accounts for 5–10% of diabetes patients [1]. 
Several events occur before the clinical onset of T1D, and our current understanding 
of the disease is largely based on small animal models that spontaneously develop 
diabetes (e.g. NOD mice): Genetic predisposition is a key component in the ﬁrst steps of 
disease development, where several HLA alleles, polymorphism in the insulin promoter 
region, and multiple loci that are involved in the regulation of the immune-system
were identiﬁed as risk factors [2]. Environmental factors might also be involved in 
priming the auto-immune assaults, such as enteroviruses, infections and the inter-
action of intestinal bacteria with the mucosal immune cells [3, 4]. The combination of 
environmental factors with the T1D pre-disposing loci triggers insulitis (у-cell-directed
auto-immune assaults). Insulitis results in speciﬁc destruction of у-cells, which leads 
to production of autoantibodies to insulin and, at later stages, autoantibodies to for 
example glutamic acid decarboxylase (GAD65), у-cell speciﬁc Zinc transporter (ZnT8)
and to the tyrosine phosphatases (IA-2 and IA-2у). Progressive у-cell loss eventually 
renders the individual insulin dependent.
The type 2 form of diabetes accounts for most cases of diabetes mellitus,
corresponding to 90-95% of the diabetic individuals [5]. Among the multiple environmental
causes of T2D, obesity is the major player in disease progression [6]. Genetic factors 
associated with у-cell dysfunction are also evident [7, 8]. Hyperglycemia occurs 
gradually and therefore, the disease usually remains unnoticed for a long period, 
which disposes the individual to vascular complications that increase over-time. The
inability of the у-cell to compensate for insulin resistance leads to progressive у-cell 
failure associated with decreased insulin production, and to a lesser extent, reduction
in BCM, resulting in loss of glycemic control and the need for medication.
In T1D patients, a daily insulin injection is the conventional approach to maintain 
homeostasis of blood glucose levels (90-110 mg/dl, or 4-6 mmol/L). This method is 
however associated with several disadvantages, where frequent episodes of hypo- 
glycemia and overall poor blood glucose control are the most common ones. 
Therefore, insulin-dependent patients remain at risk of developing long-term diabetes 
complications [9].
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Since the establishment of the Edmonton protocol [10], transplantation of deceased
donor islets in T1D patients has become a promising approach to reverse 
hyperglycemia in an experimental setting, for individuals who suffer from brittle 
diabetes and hypoglycemic unawareness [11-13]. Using the Edmonton protocol,
islets are obtained from multiple donors and are transplanted in diabetic recipients
using glucocorticoid-free immunosuppression regimen.
The isolation procedure consists of (1) enzymatic digestion of the pancreas in 
order to separate the endocrine tissue (islets containing the у-cells) from the exocrine 
tissue, (2) purifying the islets by discarding as much exocrine tissue as possible and 
(3) resting the islets in an appropriate culture medium prior to transplantation [14]. 
After transplantation and complete engraftment of the islets to the host surrounding
tissue, the graft secretes insulin in the blood stream of the recipient in response to
elevated blood glucose levels. The successful intra-portal islet transplantation has
made the liver the site of choice [12]. The major advantage of islet transplantation is
to ensure better control on blood glucose levels, thereby reducing risks of hypo- 
glycemia, and long-term complications.
Islets are, however, lost in large amounts shortly after transplantation, but also on
the long-term there are several obstacles that must be addressed to improve the 
clinical outcome [15]. For instance, the presence of the islets in the hepatic vascular 
system triggers an instant blood-mediated inﬂammatory reaction (IBMIR) which 
compromises islet engraftment, blood supply, and survival [16, 17]. Other factors 
such as islet lipo/gluco-toxicity are involved in long-term graft failure [15, 18].
The excessive use of immune-suppression drugs for maintaining immune tolerance 
towards the islets could cause islet toxicity [19, 20]. On the other hand, insufﬁcient 
immune-suppression could lead to failure in maintaining immune-tolerance and
destruction of the graft. Currently, functional and immunological assays are deployed 
in the clinics to monitor graft function (e.g. measurement of glycemia, C-peptide
levels) and to detect anti–у-cell immune attacks (e.g. measurement of anti-HLA 
antibodies) after islet transplantation [21]. However, both impaired islet function and/
or у-cell death can be involved in graft failure, and the current clinical tests are not 
suited to discriminate between у-cell loss and dysfunction. Furthermore, the
parameters measured by these tests have poor predictive value of graft damage [22]. 
Overall, islet transplantation still exhibits poor clinical long-term outcome [23].
A non-invasive method to quantify graft survival is therefore warranted, not only
for early detection of у-cell loss, but also to facilitate development of novel treatment
approaches and therapy adaptation to preserve a functional islet graft. In an ideal
setting, quantiﬁcation of BCM should be correlated with clinical functional tests for 
providing clinicians with comprehensive information about islet graft state (i.e.
survival and function). Radioactive imaging modalities such as PET and SPECT offer
high detection sensitivity of radioactive probes and are therefore of particular interest
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for у-cell imaging. First attempts to image islet grafts were performed using genetically 
modiﬁed islets that express the herpes simplex virus type 1 thymidine kinase (sr39tk).
The enzyme phosphorylates radiolabeled thymidine analogues, leading to metabolic 
trapping inside the у-cells and subsequent detection by PET. Using this strategy, islet 
grafts could be visualized by a small-animal PET after injection of the sr39tk substrate 
[18F]-FHBG, allowing for the long-term monitoring of islet transplants [24]. Similarly, 
islets genetically modiﬁed into co-expressing sr39tk and viral interleukin-10 genes, 
could be visualized by PET while being protected from immune-assaults by
modulating the local immune system [25]. Although these studies have demonstrated
the value of Nuclear Medicine Imaging for the sensitive visualization of islet grafts, the
presented approaches require genetic modiﬁcation of the islets, which limits their
clinical potential.
More recently, islets were pre-labeled with 2-[18F] ﬂuoro-2deoxy-D-glucose 
(FDG), which allowed for the detection of intra-portally transplanted islets by PET in a
rat model as well as in diabetic subjects [26, 27]. However, the short half-life of the
F-18 and temporary trapping of the probe within the islets, limits the use of the method 
for longitudinal follow-up of islet mass. In other studies, non-invasive in vivo targeting 
of у-cell surface markers with radiolabeled peptides, small molecules, antibodies 
and antibody fragments allowed for the detection of islet transplants in animal models 
and in humans [28, 29].
The most likely radionuclide-based imaging strategy to be translated into clinics 
relies on injection of radiolabeled molecular tracers that target у-cell surface markers.
The presented approach does not involve genetic manipulation of the islets prior to 
transplantation and is not limited by the half-life of the radionuclide, since the 
radiotracer can be injected any time prior to imaging. In the following section, we 
describe in vivo strategies to characterize у-cell radiotracers for in vivo quantiﬁcation
of BCM.
2.  Validation of novel ʹ-radiotracers
The importance of у-cell mass quantiﬁcation in islet grafts has triggered intensive 
preclinical research to develop non-invasive imaging techniques that can be safely 
implemented into the clinics. Hence, small animal models were widely used to
evaluate the clinical potential of new у-cell radiotracers to monitor islet grafts. Mice
and rats are convenient models, as they serve as islet donors and recipients, for 
validation of radiotracers in imaging islet grafts under normal and pathophysiological 
conditions (e.g. hyperglycemia, lipotoxicity, hypoxia, immune assaults).
Ideally, radiotracer uptake should only be dependent on the number of living 
у-cells, and expression of the radiotracer target receptor in the islets should not be 
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signiﬁcantly inﬂuenced by у-cell stress (caused by pathophysiological conditions 
mentioned above). Changes in tracer uptake due to у-cell stress could lead to erroneous
conclusions with regard to the BCM.
For initial investigation of the potential of the radiotracer in quantifying BCM, 
syngeneic models can be used, where various amounts of islets are transplanted 
and compared to tracer uptake in healthy (normoglycemic) recipients. The advantage
of this approach is that validation of the radiotracer for BCM assessment would not
be inﬂuenced by confounding factors, such as immune assaults and hyperglycemia,
etc.
To investigate the potential of the radiotracer in imaging islet grafts during hyper- 
glycemic events, diabetic recipients should be used. Several chemicals to induce
diabetes can be put into use but the two most commonly used compounds are 
alloxan and streptozotocin (STZ). Both compounds have a structure similar to glucose, 
therefore, they compete with the glucose present in the body and accumulate in the 
у-cells, leading to their destruction. It is possible to induce diabetes in most strains 
of rats and mice, although the sensitivity for the chemicals differs per strain [30].
In these models, a high percentage of the у-cells is destroyed, resulting in hyper-
glycemia. The amount of у-cells destroyed by the compounds is dependent on the 
administrated dose, giving us the advantage of controlling the level of BCM in the
pancreas, and consequently, the severity of hyperglycemia. After administration of the 
chemical it takes 5 to 7 days to reach stable hyperglycemia. Destruction of the у-cells
in the pancreas of the recipients using these compounds under different doses 
therefore allows to generate diabetic recipients, where islets can be transplanted and
studied for radiotracer uptake during mild or severe hyperglycemic events.
Allo-transplantation and xenotransplantation models can be used to verify if the radio- 
tracer can detect changes in BCM during immune-rejection. Rejection of the islets occurs
between 10-14 days after transplantation, where most of islet cells are destroyed [31]. 
Hence, imaging of islet grafts at different time-points after transplantation could
validate the use of a radiotracer in monitoring BCM prior to, during and after immune 
rejection where partial or complete loss of the graft has occurred.
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3. Suitable transplantation sites for Nuclear Medicine 
Imaging of islet grafts
In contrast to the clinical setting, in small animal models, islets are transplanted at a 
variety of sites for islet graft imaging with radiotracers. These transplantation sites are 
chosen based on the following criteria: they should exhibit an environment that allows 
у-cell survival and proper function. They should offer an environment with high sig-
nal-to-background ratio for easy visualization and quantiﬁcation of tracer uptake by 
the islets. The background signal can result from the preferred excretion routes of the 
radiotracer or the expression of the target receptor in the organs of the recipient. 
Finally, the transplantation site should allow easy histological evaluation of complete
transplants (typically by stereological approach), for accurate correlation of tracer
uptake with the graft volume that is determined by the area of у-cell markers (e.g.
insulin, nkx6.1, pdx1). Typically, fast and accurate histological evaluation of BCM can
be achieved when islets are engrafted in a small area rather than being scattered
across the transplantation site.
Imaging of human islets transplanted in the liver using 64Cu-labelled exendin was 
achieved in NOD/SCID mice [28]. Animals transplanted with the islets showed higher 
PET signal in the whole liver when compared to the control group, demonstrating the 
potential of this strategy for imaging of intraportally transplanted islets.
The skeletal muscle was previously used as a clinical transplantation site to 
accommodate islet transplants and reverse hyperglycemia [29, 32, 33]. The organ
has high angiogenic potential allowing the establishment of intra-islet blood ﬂow that
is comparable to the native environment of pancreatic islets [33]. The transplantation 
procedure is minimally invasive and relatively easy to perform. Furthermore, the islets
can be transplanted in muscle tissues located far away from the radiotracer excretion
routes (e.g. renal excretion) and organs that are known to express the target receptor.
Finally, easy in vivo quantiﬁcation of tracer uptake and fast histological analysis of 
complete transplants in preclinical studies is possible, due to the focal engraftment
in the muscle. Using this model, islet imaging was achieved by 111In-exendin in a
clinical case, where islet mediated uptake of the tracer was clearly visualized by 
SPECT planar projections [34].
The subcutaneous space has been used for islet transplantation in humans 
given its easy accessibility and the safety of the procedure. However, the site exhibits 
low angiogenic potential, which represents an obstacle for proper graft survival and 
functioning. The large availability of subcutaneous spaces and the possibility to 
transplant islets into a small distribution area offer similar advantages as described 
above for the skeletal muscle. Using this model, previous studies demonstrated that 
human islets transduced with the simplex virus type 1 thymidine kinase (HSV1-tk) can 
be targeted in vivo with [18F]FHBG and visualized by PET in mice [24].
515893-L-bw-eter
Processed on: 12-12-2017 PDF page: 24
24
Chapter 2
4.  Background and aims of the thesis
The glucagon-like peptide-1 (GLP-1) receptor is a promising target receptor for у-cell 
imaging [35]. It is a G-protein coupled receptor, which internalizes the endogenous
ligand GLP-1 after binding. Since GLP-1 is quickly degraded by dipeptidyl peptidase-4
(DPP-4) in the blood [36] and has a half-life time that is less than 2 minutes [37],
stable GLP-1 analogues are used to target the GLP-1R, such as exendin-3 and 
exendin-4 [38-40].
The speciﬁcity of radiolabeled exendin towards the у-cells has been a matter of
debate. In fact, т-cells were reported to express the receptor [41-43], while in other
studies, the GLP-1R was shown to be speciﬁc to the у-cells [44-46]. Most importantly, 
it was demonstrated that 111In-exendin uptake in the pancreas correlates with BCM
and not with тcell mass [47]. It was in fact demonstrated that accumulation of 111In-
exendin-3 in the у-cells allows to measure differences in BCM in the pancreas of rat 
models for diabetes, as well as in healthy and diabetic subjects using SPECT imaging, 
without apparent interference of the тcells on the measurements [48].
Non-invasive measurement of the BCM in islet grafts using a similar approach 
could allow to improve the clinical outcome of islet transplantation. Whether the
radiotracer is suitable to quantify BCM after islet transplantation was, however, not yet
demonstrated. Moreover, it was previously reported that hyperglycemia could 
down-regulate the expression of the GLP-1R, which might occur in islet recipients 
with poorly regulated blood glucose levels [49]. Down-regulation of the GLP-1R could 
be misleading when measuring the true BCM, using 111In-exendin, and must therefore 
be investigated.
The aim of this thesis was to characterize the targeting properties of 111In-
exendin-3 in transplanted islets and to validate the radiotracer utility for non-invasive 
quantiﬁcation of BCM using healthy (control) and diabetic C3H mouse recipients.
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Abstract
Islet transplantation is a novel promising strategy to cure type 1 diabetes. However, 
the long-term outcome is still poor, because both function and survival of the 
transplant decline over-time. Non-invasive imaging methods have the potential to 
enable monitoring of islet survival after transplantation and the effects of immuno-
suppressive drugs on transplantation outcome. 111In-labeled exendin-3 is a promising 
tracer to visualize native and transplanted islets by SPECT (Single Photon Emission 
Computed Tomography). In the present study, we hypothesized that islet micro-
vasculature plays an important role determining the uptake of exendin-3 in islets 
when monitoring transplant survival. We observed 111In-exendin-3 accumulation in 
the transplant as early as three days after transplantation and an increase in the 
uptake up to three weeks post-transplantation. Islet-revascularization correlated with
the increase of uptake of 111In-exendin-3, whereas fully re-established islet vasculature
coincided with a stabilized uptake of the radiotracer in the transplant. Here, we demonstrate
the importance of islet vasculature for in vivo delivery of radiotracers to transplanted 
islets and we demonstrate that optimal and stable uptake of exendin four weeks after 
transplantation opens the possibility for long-term monitoring of islet survival by 
SPECT imaging.
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Introduction
Reversal of type 1 diabetes by transplanting pancreatic islets has emerged as a
promising therapeutic approach [1, 2]. However, insulin independence shows a rapid 
decrease and can hardly be preserved beyond 5 years after the intervention [3]. 
Moreover, several studies reported impaired islet survival after liver transplantation,
which was caused by insufﬁcient revascularization [4] and triggering of blood-mediated
inﬂammatory reactions [5], along with lipo and/or gluco-toxicity [6-8].
Current functional tests cannot determine whether graft failure is caused by 
functional impairment of у-cells or у-cell loss, as many factors can be involved in 
this process (i.e. immune rejection, decline in islet function through metabolic or
inﬂammatory stress) [3, 9]. Biomedical imaging techniques can therefore be used to 
monitor islet survival in addition to islet function measured by clinical testing and can 
therefore contribute to future clinical decision making regarding treatment assignment 
or adaptation. Pre-labeling of islets with super-paramagnetic iron oxide particles 
(SPIOs) for MR imaging of islet transplants has been introduced a decade ago [10]. 
Further studies demonstrated that human islets transplanted in rodents can be
monitored and quantiﬁed by MRI up to 6 months post-transplantation [11]. Labeling
of the islets with SPIOs prior to transplantation is therefore a promising technique for
clinical studies [12].
In other studies, radioactive-based imaging methods were used for their advanced 
detection sensitivity of in vivo tracer uptake by transplanted or native islets [13, 14].
In particular, SPECT imaging after injection of 111In-labeled exendin was reported as
a promising strategy to non-invasively visualize engrafted islets, as well as to visualize
and quantify BCM in the pancreas of healthy and diabetic subjects [15, 16]. Therefore, 
this tracer could be suitable for repeated longitudinal clinical imaging of islet transplants.
The advantage of the tracer is the ability of repeated scanning without requiring
pre-labeling of the islets prior to transplantation. However, the targeting properties of
the radiotracer to the islet grafts early after transplantation may depend on the 
vasculature that is disrupted after islet isolation [17-19].
Imaging of islet grafts in the skeletal muscle has been demonstrated previously
[16], and allows monitoring of the transplant since the islets remain localized in a 
small engraftment area, where speciﬁc uptake can be easily discriminated from the 
surrounding tissue. Making use of this transplantation model, we determined the 
correlation between islet graft revascularization and the uptake of 111In-exendin-3 in 
the transplant for several weeks following islet transplantation.
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Research Design and Methods
Animals. Female C3H/HeNCrl mice (22–30 g) were purchased from Charles River 
(Calco, Italy). All experiments were conducted in accordance with Radboud University 
guidelines on humane care and use of laboratory animals, and were approved by the
Animal Ethical Committee of the Radboud University, Nijmegen, The Netherlands.
Pancreatic islet isolation and transplantation. Pancreatic islets were isolated from
8 weeks-old female C3H/HeNCrl mice by collagenase digestion method. Mice were 
euthanized and 2 ml of cold RPMI 1640 (Invitrogen, Carmarillo, CA, USA) containing 
collagenase-V (0.9 mg/ml, Sigma Aldrich, St Louis, MO, USA) was infused via the 
pancreatic duct. Pancreata were collected in RPMI medium with collagenase and 
were digested at 37°C for 12 min. The digested tissue was washed twice in RPMI 
medium and was ﬁltered through a 500 μm ﬁlter to separate the islets from undigested 
tissues. Islets puriﬁcation was performed on a discontinuous Ficoll gradient (1.118,
1.096 and 1.037 g/ml, Cellgro by Mediatech Inc., Manassas, VA, USA), respectively, 
and centrifuged at 625 x g for 16 min without brake. Islets were collected from the 
aqueous phase between the ﬁrst and second layer and washed twice with RPMI
medium. Finally, islets were incubated overnight in a humidiﬁed 5% CO2 atmosphere 
at 37°C in RPMI 1640 medium containing L-glutamine (Sigma), penicillin-streptomycin
(10 mg/ml, Sigma Aldrich) and 10% v/v fetal calf serum (HyClone, Celbio, Logan, UT, 
USA). Islets were counted and hand-picked under a bright ﬁeld microscope. Eight 
hundred islets were transferred to an eppendorf tube and centrifuged at 62 x g for 
2 minutes and aspirated in a canula by a Hamilton syringe. Syngenic transplantation 
was performed in the calf muscle, parallel to the ﬁbula, using needles with a 0.8 mm
diameter. To determine the exact number of transplanted islets, the canula was 
washed with fresh medium which was collected in the eppendorf tube used for 
preparation of the islets. The exact number of transplanted islets was determined by 
subtracting the remaining islets in the tube from the initially counted number.
Radiolabeling of exendin-3. [Lys40(DTPA)]-exendin-3 was purchased from Peptide 
Specialty Laboratories (Heidelberg, Germany). Peptide labeling with In-111 was performed
as previously described [15]. Radiochemical purity was determined by ITLC and 
radiolabeled exendin-3 was puriﬁed by solid-phase extraction using a HLB-cartridge
(Waters, Etten-Leur, The Netherlands) prior to animal injection as previously reported 
[15]. All animals were injected with 0.1 μg of exendin-3 corresponding to approximately 
15 MBq.
Binding assay on isolated islets. The binding of radiolabeled exendin-3 to islets 
was examined on isolated islets from C3H mice. After overnight recovery from
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isolation procedure, islets were collected and the medium was removed by 
centrifugation as described above. The islets were diluted in binding buffer (RPMI 
1640 containing 0.5% BSA (w/v)) and 100 or 300 islets (triplicate) were added to 
24-transwell plates (Corning B.V. Life Sciences, Amsterdam, The Netherlands) and
counted under a bright-ﬁeld microscope (Meyer Instruments, Huston TX, USA). The 
islets were washed with 200 μl of binding buffer and 1.5 fmol of In-111-exendin-3 in 
200 μl of binding buffer were added. Excess of unlabeled exendin-3 (corresponding 
to 0.62 nmol) was added to 3 additional wells per condition to examine GLP-1R 
mediated binding. After 4 h incubation at 37ºC the islets were washed twice with 
binding buffer, the transwells containing the islets were measured in a ф-counter 
(Wallac 1480 Wizard, Perkin Elmer, Boston, MA, USA) and the bound fraction was
determined.
Imaging procedure and data acquisition. Mice were injected intravenously with 15 
MBq of exendin-3 and were scanned 1 hour after injection. Scans were performed 
with a small animal U-SPECT-II/CT system (MILabs, Utrecht, The Netherlands) with a
1 mm multi-pinhole ultra-high sensitivity mouse collimator for 50 minutes. Mice were 
scanned after 3 days, 1, 2, 3, 4, 5 or 6 weeks post-transplantation. All mice were
scanned twice with 7 days difference, under the same parameters. Immediately after 
the second SPECT acquisition, mice were euthanized and calf muscles containing
the transplant were dissected and were put in 4% paraformaldehyde inside eppendorf 
tubes and were scanned ex vivo with the same settings. All images were reconstructed
with OSEM (3 iterations, 16 subsets, voxel size 0.4 mm) using the U-SPECT-Rec 
software (MILabs, Utrecht, The Netherlands). CT scans were performed in full/
accurate mode or partial/fast mode under 615 μA/s and 65 kV. For quantiﬁcation of 
SPECT images, a volume of interest (VOI) was manually drawn around the observed
uptake in the transplantation site and the background was subtracted by using the 
same VOI applied on the contra-lateral calf muscle, which contained no transplant. 
Data were corrected for the injected dose and converted to Bq by using external
standards with known activity scanned and reconstructed with the same settings.
Histological analyzes. Muscles were ﬁxed in 4% paraformaldehyde and embedded
in parafﬁn after SPECT acquisition. For autoradiography, muscles were sliced into 4 μm 
sections and were exposed to an imaging plate (Fuji Film BAS-SE 2025, Raytest,
Straubenhardt, Germany) for 7 days. Images were visualized with a radiolumino-
graphy laser imager (Fuji Film BAS 1800 II system, Raytest, Straubenhardt, Germany). 
Quantitative analysis of the autoradiographical images was performed using AIDA 
Image Analyzer software (Raytest GmbH, Straubenstadt, Germany). Data were
acquired by drawing ROIs around each transplant as well as around the standards 
with known amount of radioactivity. Subsequently, sections were stained with hema-
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toxylin-eosin (HE) to conﬁrm the presence of pancreatic islets. Finally, for immuno-
histochemical staining of insulin, consecutive sections underwent antigen retrieval
for 10 min in 10 mM citrate pH 6 at 96°C and blocked with 1% BSA in PBS for 
30 minutes and endogenous peroxidase activity was blocked with 3% H2O2 in PBS
for 30 minutes. Staining was performed using anti-insulin rabbit antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) diluted 1/500 for 2 hours at room temperature. 
Sections were incubated with swine anti-rabbit conjugated with peroxidase, for 1 
hour at room temperature and washed with PBS. The staining was developed with 
Bright DAB (Immunologic, Duiven, The Netherlands) and sections were visualized 
under bright-ﬁeld microscopy. To normalize the autoradiography measurements by
the corresponding transplant surface, the outline of insulin-positive cells of consecutive 
sections was manually drawn in imageJ (data are expressed as Bq/mm2). To normalize 
SPECT data by the size of the transplant, the volume was calculated by multiplying 
the insulin positive surface per level by the distance separating each analyzed 
section, that is 50 μm. For determination of vascular density, consecutive sections
were blocked with 1% BSA in PBS for 30 minutes and stained with anti-insulin 
guinea-pig antibody (Dako, Heverlee, Belgium) diluted 1/1000 and anti-VEGFR-2
rabbit antibody (Cell signaling, Danvers MA, USA) diluted 1/200 for 2 hours at room 
temperature. Sections were next incubated with goat anti-guinea pig Alexa 488 
(1/200; Life technology, Dallas, TX, USA) and goat anti-rabbit Alexa 594 (1/200; Life 
technology), respectively, for 1 hour at room temperature. To conﬁrm the expression
of the GLP-1R, sections were blocked with 1% BSA in PBS for 30 minutes and stained 
with anti-GLP-1R rabbit antibody (Abcam, Cambridge, UK) diluted 1/500 for 2 hours
at room temperature. Sections were next incubated with goat anti-rabbit Alexa 594 
diluted 1/300 for 1 hour at room temperature. Sections were mounted and visualized 
with an epiﬂuorescence microscope (Axioskop Zeiss, Thornwood, NY, USA).
Statistical analysis. Measurements are given as means ± SEM. Multiple comparisons
were analyzed by one-way ANOVA and Bonferroni post-hoc test, P value <0.05 was 
considered statistically signiﬁcant. Data processing was performed with Graphpad 
Prism 5 (GraphPad Software, San Diego, CA, USA). Animals that showed no SPECT 
signal as well as no histological signs of insulin staining, were excluded from the 
study.
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Results
Radiolabeled exendin-3 binds to the GLP-1R on mouse islets in vitro. Incubation 
of 1.5 fmol of radiolabeled exendin-3 with 100 islets for 4 hours resulted in the binding
of 9.1x10-3 fmol (ﬁg. 1). Binding of radiolabeled exendin-3 was reduced to 3.3x10-3
fmol in the presence of excess of unlabeled exendin-3 (p<0.05). Binding of 
radiolabeled exendin-3 was two-fold higher when added to 300 islets (17.5x10-3 fmol) 
and binding was successfully decreased to 3.7x10-3 fmol by applying an excess of 
unlabeled exendin-3 (p<0.001), which conﬁrmed the expression of the GLP-1R.
Exendin-3 uptake in the skeletal muscle is localized in the transplanted islets. In
order to determine whether the uptake of exendin-3 originates from the transplant 
within the skeletal muscle, we performed ex vivo autoradiography of the muscle 
regions that contain the islets, followed by histochemical staining. As evidenced in
ﬁgure 2 (A-F), there was accumulation of 111In-exendin-3 within well-localized regions
of the muscle after 3 days, 1, 2, 3, 4 and 6 weeks in the islet transplants. Sections 
were next analyzed by HE staining, where the uptake was conﬁrmed as islet-speciﬁc. 
Immunohistochemical staining of muscle sections with an anti-insulin monoclonal
antibody conﬁrmed that the transplant predominantly consisted of у-cells (ﬁg. 2G).
Quantitative analysis of 111In-exendin-3 accumulation within transplanted islets 
by autoradiography was 0.48 ± 0.068, 0.99 ± 0.16, 1.35 ± 1.08, 2.97 ± 0.27, 2.73 ±
0.4 and 3.45 ± 0.34 Bq/mm2 at 3 days and 1, 2, 3, 4, 6 weeks after transplantation,
Figure 1 In-vitro binding of radiolabeled exendin-3 to mouse pancreatic islets.
Quantiﬁcation of radiolabeled exendin-3 (black columns) shows higher binding to 300 islets
than to 100 islets. Blocking of the receptor with an excess of unlabeled exendin-3 (white 
columns) signiﬁcantly decreased the binding. Data are shown as means ± SEM from 3 
experiments. *p<0.05, ***p<0.001 compared with the corresponding amount of islets,
whereas ##p<0.01 compared with 100 islets.
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Figure 2  Ex-vivo measurement of exendin-3 uptake by transplanted islets.
(A-F) Autoradiography of muscle sections shows hotspots of In-111 accumulation. Histochemical
staining of the corresponding autoradiography section shows co-localization between the uptake
of exendin-3 and the transplant. (G) Adjacent sections were stained with anti-insulin mAb to conﬁrm
the presence of у-cells (brown). (H) Quantiﬁcation of In-111 uptake (expressed in becquerel/mm2)
according to autoradiography shows signiﬁcant increase between 3 days to 3 weeks-old transplants 
(***p<0.001) and stabilized uptake between 3 and 6 weeks post-transplantation.
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respectively (ﬁg. 2H). Immunostaining of the GLP-1R with a polyclonal antibody
conﬁrmed the expression of the receptor in the transplants (ﬁg. 3).
The density of newly formed blood vessels in the transplant correlates with the 
uptake of exendin-3. To investigate whether revascularization of transplanted islets
affects the uptake of radiolabeled exendin-3, VEGFR-2 and insulin expression was
quantiﬁed to determine islet microvasculature and у-cells area, respectively (ﬁg. 4).
The ﬁrst vascular structures in the graft were observed 3 days after transplantation. At that
time, VEGFR-2 positive endothelial cells were mostly surrounding the transplant (ﬁg. 4A-B).
Figure 3 GLP-1R expression is maintained in the islets early after transplantation.
Representative images of 3 days (A-B), 2 weeks (C-D) and 4 weeks-old transplants (E-F)
stained for GLP-1R (red) and insulin (green).
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Figure 4  Histological analysis of islet revascularization in the skeletal muscle.
(A-L) Representative images of 3 days to 6 weeks-old islet transplants for which у-cells were 
stained with anti-insulin (green) and the ingrowing VEGFR2-expressing capillaries (red). All sections
were counter-stained with DAPI (blue). (M) Quantiﬁcation of vascular density within the insulin 
positive area shows signiﬁcant increase in number of vessels from 3 days to 3 weeks (***p<0.001).
(N) Initiation and increase of islet vascular density correlates with increasing exendin-3 uptake 
(Pearson r=0.83). Data are shown as means ± SEM from 4-5 animals.
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There was notable progress of angiogenesis one week after transplantation, as more 
endothelial cells had inﬁltrated the islets (ﬁg. 4C-D). Intra-islet vasculature was more 
prominent between 2 weeks and 6 weeks after transplantation, as vessels clearly had 
penetrated from the periphery into the core of the transplant (ﬁg. 4E-L). Quantitative
analysis of revascularization showed notable progress between 3 days and 3 weeks
(p<0.001) and a stablized vascular density between 3 and 6 weeks (ﬁg. 4M). First 
signs of revascularization coincided with low exendin-3 uptake by 3-day old grafts
and increase in islet vascular density correlated with the uptake of exendin-3 by the
islets (Pearson correlation coefﬁcient r=0.83) (ﬁg. 4N).
In vivo visualization of islet transplants is dependent on islet revascularization.
To assess the correlation between intra-islet vascular density and the tracer concentration
in the transplant, SPECT scans were performed at different time-points after trans-
plantation. SPECT visualized 3 days to 6 weeks-old transplants within the skeletal 
muscle (ﬁg. 5A). After 3 days, 12.5 ± 2.7 kBq/mm3 accumulated in the transplants, 
which further increased up to 63 ± 4.7 kBq/mm3 at 4 weeks and remained similar up
to 6 weeks after transplantation (68 ± 3.2 and 67 ± 2.5 kBq/mm3, for week 5 and 6, 
respectively) (ﬁg. 5B).
Ex vivo acquisitions were in line with the in vivo data, as signal could be detected
after 3 days and was increased over time (ﬁg. 6).
To determine the time-point after which multiple imaging sessions result in 
reproducible assessment of 111In-exendin-3 uptake, each mouse was scanned twice
with 7 days of interval, starting 3 days, 1, 2, 3, 4 or 5 weeks after transplantation (ﬁg. 7A). 
Quantitative analysis revealed an increase in the signal 7 days after the initial scans 
with stabilization being observed between 3 and 4 weeks-old transplants (ﬁg. 7B).
Increase in uptake was independent from the transplant size, since the uptake was 
normalized by the volume of the transplant. Two transplants which were not visible 
3 days or 1 week after transplantation, both became detectable at the time of the 
second scan.
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Figure 5  In-vivo detection of pancreatic islets transplanted in the calf muscle. 
(A) Representative images of C3H mice with transplanted islets. Signal was detected 3 days, 1, 
2, 3, 4, 5 and 6 weeks after transplantation (white arrows). (B) Quantitative analysis of the
SPECT images showed a signiﬁcant increase in the uptake of 111In-exendin-3 between 3 days 
and 3 weeks post-transplantation (***p<0.001) and a stabilized uptake between 3 and 6 weeks. 
Data are presented as kBq/mm3 and are normalized by the injected dose.
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Figure 6 Ex-vivo detection of pancreatic islets transplanted in the calf muscle.
Representative images from ex-vivo scans of dissected muscles containing the transplant.
Figure 7 In-vivo detection of pancreatic islets at different weeks.
(A) Representative images from in-vivo scans at two different time-points with one week interval.
Transplants are indicated with white arrows. (B) SPECT quantitative analysis where t2-t1
corresponds to 7 days interval between both scans shows improved uptake of 111In-exendin-3 
and ﬁrst signs of stabilization of tracer uptake between 3 weeks and 4 weeks post-transplantation.
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Discussion
In the present study, we examined the inﬂuence of islet graft revascularization on the
targeting characteristics of radiolabeled exendin-3, a radiotracer with great potential 
as imaging biomarker for non-invasive assessment of у-cell survival after transplan-
tation. We demonstrated that an increase in vascular density, between 3 days and 3 
weeks after transplantation, correlated with an increase in the accumulation of 111In-
exendin-3 in the transplant. Furthermore, in mice in which no signal could be detected
three days or one week after transplantation, islet grafts exhibited a detectable uptake
at later time-points where vascularity improved. When the vascular bed had been 
established after 4 weeks, the uptake of exendin-3 indeed stabilized in repeated scans,
indicating that islet revascularization has a direct inﬂuence on the targeting of transplanted
islets after in vivo injection of radiotracers. Imaging of islet transplants with radiotracers 
will therefore reveal reproducible results starting 4 weeks after transplantation, the 
time-point after which the vascular bed of the transplants appears to have been 
established.
These ﬁndings indicate that recovery of islet vascular network is a prerequisite for 
reproducible longitudinal evaluation of viable islet grafts. First, complete restoration 
of islet vasculature improves the transplant signal-to-background ratio which facilitates
the quantitative assessment of exendin-3 uptake. Secondly, reproducible uptake of
exendin-3 is a requirement to accurately quantify BCM, and changes in the uptake
after vasculature has recovered would most likely reﬂect у-cell loss.
Angiogenesis in recipients with long history of diabetes might be suboptimal [20].
Furthermore, graft angiogenesis rate is dependent on the transplantation site [21].
Therefore, the optimal time-point after which reproducible imaging results are obtained,
might be affected by these parameters. The technique will allow, however, to quantify 
islet survival, months, if not years after transplantation, where failure in maintaining 
normoglycemia could occur even after successful engraftment of the islets [3].
It was previously reported that islets transplanted in liver can be visualized with 
small-animal PET, where the uptake of 64Cu-labeled exendin in the liver of transplanted
animals was higher as compared to those of the control animals 12 days after 
transplantation [13]. Here we report the skeletal muscle as a suitable platform for 
characterization of tracer targeting properties to the islets. Using this model, we could 
investigate the role of the revascularization of the transplant on radiotracer uptake,
since in this model the revascularization could be easily quantiﬁed ex vivo by histology.
This transplantation site could be further used to characterize the targeting properties 
of novel у-cell radiotracers and to further evaluate existing ones with the advantage 
of fast histological evaluation of complete transplants.
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In conclusion, this study revealed that islet revascularization is a key physiological process
when monitoring islet transplants after in vivo targeting of the graft with у-cell tracers.
Stable and reproducible uptake of exendin was achieved starting 4 weeks after trans-
plantation, indicating that longitudinal assessment of islet survival by SPECT imaging 
can reproducibly be performed after this time point.
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Abstract
Pancreatic islet transplantation is a promising therapy for patients with type 1 diabetes. 
However, the duration of long-term graft survival is limited due to inﬂammatory as well
as non-inﬂammatory processes and routine clinical tests are not suitable to monitor
islet survival. 111In-exendin-SPECT (single photon emission computed tomography) 
is a promising method to non-invasively image islets after transplantation and has the
potential to help improve the clinical outcome. Whether 111In-exendin-SPECT allows
detecting small differences in BCM and precisely measuring the actual volume of 
islets that were successfully engrafted has yet to be demonstrated. Here, we evaluated 
the performance of 111In-exendin-SPECT by using an intramuscular islet transplantation
model in C3H mice. In vivo imaging of animals transplanted with 50, 100, 200, 400 
and 800 islets revealed an excellent linear correlation between SPECT quantiﬁcation 
of 111In-exendin uptake and insulin-positive area, demonstrating that 111In-exendin-
SPECT accurately measures BCM, whereas SPECT signal originated from islets that
were successfully engrafted. The high sensitivity of the method allowed measuring 
small differences in graft volumes, as well as grafts that contained less than 50 islets. 
The presented method is reliable, convenient and holds great potential for non-invasive
monitoring of BCM after islet transplantation in humans.
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Introduction
Transplantation of islets of Langerhans is a promising treatment for patients with type
1 diabetes (T1D). The short-term results of islet transplantation in normalizing blood 
glucose levels are encouraging [1]. However, the rate of insulin-independency drops
to less than 15% after 5 years [2]. Although the loss of transplanted beta cells quickly 
renders patients insulin-dependent in a life-time perspective, the remaining graft 
function still exerts a positive effect on glucose homeostasis, reducing late complications
and further progression of micro-vascular diseases [3]. Furthermore, the islet grafts 
lower the amount of insulin required to maintain acceptable blood glucose levels 
thereby preventing potentially lethal, severe hypoglycemia by improved glycemic control.
However, in view of the considerable side effects caused by the immunosuppressive 
therapy required to prevent graft rejection, improved survival of the transplanted islet 
is desirable. In order to optimize islet replacement therapy and to prevent loss of graft
function, numerous approaches are currently under investigation, including modiﬁed
immunosuppressive treatments [4-6] and islet encapsulation strategies [7, 8] treatment 
with growth factors and other hormones, as well as alternative sources for beta cells (i.e. 
stem cells, tissue bioengineering) [9-14]. In order to monitor the graft volume and optimize 
new strategies for beta cell replacement a non-invasive technology to visualize viable 
transplanted islets in vivo is warranted. Such a method should be quantitative and sensitive
in order to allow the detection of small changes in the number of surviving islets.
A promising approach to visualize transplanted islets in vivo has been demonstrated
by Saudek et al., using Magnetic Resonance Imaging (MRI). The group described 
MRI of islets that had been labeled with super-paramagnetic iron oxide particles 
(SPIOs) prior to transplantation [15]. The feasibility of longitudinal non-invasive 
monitoring of islet transplants was further demonstrated in animal models by Evgenov 
and co-workers, successfully monitoring islet transplants for up to 188 days after 
surgery [16]. Pre-labeling of the islets with SPIOs is therefore a promising method 
with clinical potential [17].
Alternatively, radionuclide imaging modalities were used because of their high 
detection sensitivity of transplanted islets. First results of PET imaging of an islet graft
were published in 2006, using islets which were transfected with an insulin promoter-
dependent reporter gene that leads to trapping of the PET probe 18F-FHBG in islet
grafts [18]. In another experiment, islets were pre-labeled with 18F-ﬂuorodeoxyglucose 
(18F-FDG) and post-transplantation events could be monitored for up to 6 hours after
transplantation [19].
More recently, speciﬁc targeting of beta cells after in vivo injection of radiolabeled
exendin followed by SPECT imaging was reported as a promising strategy to non- 
invasively visualize and quantify BCM in the pancreas of rodents, as well as in healthy 
and diabetic individuals [20, 21]. Similar exendin-based radiotracers were applied for
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non-invasive imaging of islet grafts in rodent transplantation models as well as in
human skeletal muscle [22-24]. Although the use of such tracers in a clinical setting 
of islet transplantation is highly warranted, establishing the correlation between true 
beta cell mass and the uptake of the radiotracer in vivo is an essential validation step 
before such studies could be conducted in humans. Such decisive step has not been 
performed for GLP-1R imaging of islet transplants.
In the present study, we measured the uptake of 111In-exendin-3 in transplants 
consisting of different amounts of islets in the calf muscles of C3H mice by 
non-invasive SPECT imaging in vivo and validated 111In-exendin as a quantitative 
biomarker for assessment of transplanted beta cell volumes.
Research Design and Methods
Animals. Female C3H/HeNCrl mice (22–30 g) were purchased from Charles River
(Calco, Itlay). Experiments were approved by the Animal Ethical Committee of the
Radboud University, Nijmegen, The Netherlands.
Pancreatic islet isolation and transplantation. Pancreatic islets were isolated from 
6-8 weeks old mice by a collagenase digestion method. Brieﬂy, mice were euthanized 
and 2 ml of cold RPMI 1640 (Invitrogen, Carmarillo, CA, USA) containing collagenase 
type V (1 mg/ml; Sigma Aldrich, St Louis, MO, USA) were infused into the pancreatic 
duct in situ. Perfused pancreata were collected in serum-free RPMI medium and 
kept on ice until enzymatic digestion at 37 °C for 12 min. Islets were puriﬁed on 
a discontinuous Ficoll gradient of following densities: 1.118, 1.096 and 1.037 g/ml
(Cellgro by Mediatech Inc., Manassas, VA, USA) and islets were collected between
the second and the third fraction. Islets were cultured overnight in a humidiﬁed 5 % 
CO2 atmosphere at 37 °C in RPMI 1640 medium supplemented with L-glutamine 
(Sigma Aldrich, St. Louis, MO, USA), penicillin-streptomycin (10 mg/ml; Sigma
Aldrich) and 10 % (v/v) fetal calf serum (HyClone, Celbio, Logan, UT, USA). Islets were
counted and hand-picked under bright ﬁeld microscope and 50, 100, 200, 400 or 800 
islets were transplanted in the calf muscle, parallel to the ﬁbula, using needles with a 
0.8 mm diameter. The exact number of transplanted islets was determined by 
subtracting the remaining islets in the tube from the initially counted number.
Radiolabeling of exendin-3. [Lys40(DTPA)]-exendin-3 was purchased from Peptide 
Specialty Laboratories (Heidelberg, Germany). Tracer labeling with In-111 was 
performed as previously described [20]. Radiochemical purity was determined by
ITLC and radiolabeled exendin-3 was puriﬁed by solid-phase extraction using a 
HLB-column as previously reported [20].
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SPECT acquisition. Mice with 50, 100, 200, 400 and 800 islets were scanned after 4 
weeks. All mice (n=4-5) were injected with approximately 15 MBq of 111In-exendin-3
(peptide dose 0.1 μg in 200 μl PBS, 0.5 % BSA) in the tail vein. SPECT scans were
acquired 1 h post-injection on a U-SPECT-II/CT dedicated small-animal scanner 
(MILabs, Utrecht, Netherlands) for 50 min with a high sensitivity mouse collimator (1.0 mm 
pinholes). Computed tomography (CT) was performed subsequently for anatomical 
reference. Standards of 74 kBq, 55 kBq, 37 kBq and 18 kBq in 50 μl volume each, 
were scanned under the same parameters as reference for quantiﬁcation. Images were 
reconstructed with voxel size of 0.4 mm, 3 iterations and 16 subsets, using U-SPECT-II
reconstruction software (MILabs, Utrecht, The Netherlands). No attenuation correction 
was applied. No ﬁltering was performed after reconstruction of the images. The VOI
was drawn over the islet transplant region, total voxel intensity registered in the islet 
graft was corrected by the mean of 3 measurements of contra-lateral control muscle,
to subtract the background signal originating from the muscle tissue. The absolute 
activity (in kBq) was calculated by multiplying the corrected voxel intensity value with
the calibration factor determined by quantitative analysis of standards with known 
radioactivity and data were normalized by the injected dose.
Morphometric analysis of the transplant. Immediately after SPECT acquisitions, 
mice were euthanized, muscles were ﬁxed in 4% paraformaldehyde and embedded 
in parafﬁn, then sectioned into 4 μm slices for autoradiography analysis or for 
determination of insulin volume by immunohistochemistry. For autoradiography 
analysis, muscle sections were exposed to an imaging plate (Fuji Film BAS-SE 2025, 
Raytest, Straubenhardt, Germany) for 7 days and images were visualized with a ra-
dioluminography laser imager (Fuji Film BAS 1800 II system, Raytest, Straubenhardt, 
Germany) and were ﬁnally stained with hematoxylin-eosin (HE) to conﬁrm the 
presence of pancreatic islets. For determination of insulin volume, insulin staining 
was performed in muscle sections. Antigen retrieval was done using 10 mM sodium
citrate buffer, pH 6.0, for 10 min (Thermo Scientiﬁc PT module, Lab Vision, USA).
Blocking of endogenous peroxidase activity was performed by incubation with 0.6 % 
H2O2 in 40 % methanol / 60 % PBS for 30 min at RT in the dark. An additional blocking 
step was done with 5 % swine serum in PBS for 30 min at RT. Primary anti-insulin 
antibody (cat. sc 9168, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was 
applied at a dilution of 1:50 (in PBS containing 1 % BSA w/v). Subsequently, sections 
were washed with PBS and incubated with secondary horseradish peroxidase-con-
jugated swine-anti-rabbit IgG (1:50) (cat. P0217, Dakopatts, Copenhagen, Denmark) 
in PBS containing 1 % BSA w/v for 30 min at RT. The staining was visualized with di-
aminobenzidine (PowerVisionTM DAB substrate system, Immunologic, Duiven, The
Netherlands) and nuclei were counterstained with haematoxylin. To determine the 
volume of the transplant, sections were scanned with Pannoramic250 Flash II scanner 
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(3D Histech, Budapest, Hungary), beta-cell surface was manually drawn around
insulin positive region using Photoshop CS6, and the surface was multiplied by the
distance separating each analyzed section, which is 40 μm.
Statistical analysis. Correlation studies were expressed as Pearson r. Data processing
was performed with Graphpad Prism 5 (San Diego CA, USA).
Results
111In-exendin accumulation in the muscle co-localizes with islet transplants.
To check whether 111In-exendin-3 signal originates from transplanted islets, C3H 
mice were transplanted with 800 islets in the calf muscle and were injected with 
111In-exendin-3 four weeks after transplantation, where accumulation of the radiotracer 
in the islets becomes reproducible [25]. Autoradiographical analysis of muscle 
sections showed tracer accumulation in well localized regions of the tissue (ﬁgure 1A) 
and immunostaining for insulin conﬁrmed that the radioactive signal originated from 
the islets (ﬁgure 1B).
Figure 1 111In-exendin-3 uptake in the skeletal muscle is co-localized with islet transplants.
(A) Autoradiography of muscle sections shows local accumulation of 111In-exendin-3 (black 
arrows), the limits of the muscle section are shown by the dashed line. (B) Immunostaining of 
the corresponding autoradiography section shows co-localization between beta cells (brown) 
and 111In-exendin-3.
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Figure 2 Uptake of 111In-exendin by islet transplants is in linear correlation with 
transplant size.
(A) SPECT imaging detected the grafts initially transplanted with 50, 100, 200, 400 or 800 islets
with high sensitivity, 4 weeks after transplantation (white arrows). (B) 111In-exendin uptake 
(expressed in kilobecquerels, kBq) was dependent on transplant size (n=4-5). (C) SPECT signal
(expressed in kBq) correlated linearly with graft insulin-positive volume (μm3) as determined by
morphometric analysis of transplant sections (Pearson r=0.89).
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111In-exendin uptake by transplanted islets correlates linearly with BCM. 111In-
exendin-3 uptake in grafts containing various amounts of islets was detected and
clearly delineated by SPECT signal (ﬁgure 2A). Quantitative analysis of SPECT signal 
originating from the transplant revealed differences in 111In-exendin-3 accumulation 
depending on the number of initially transplanted islets, where the uptake was 5.9
kBq ± 2.4, 22.9 kBq ± 4.8, 30.1 kBq ± 10.1, 60.9 kBq ± 9.8 and 88.7 kBq ± 11.5, in 
muscles transplanted with 50, 100, 200, 400 and 800 islets, respectively (ﬁgure 2B).
Immunohistochemical determination of graft volume was performed in all groups of 
mice (ﬁgure 2C). Plotting of SPECT data against the insulin staining volume revealed 
an excellent linear correlation between 111In-exendin uptake and transplant size
(pearson r=0.89).
Discussion
The aim of this study was to measure the uptake of 111In-exendin by islet transplants 
compared to у-cell mass in a muscle model of islet transplantation. We have
demonstrated that tracer uptake and beta-cell volume correlate in an excellent linear 
manner. In addition, reliable visualization of transplants with various numbers of islets 
indicates that this method is suitable to quantify small differences in viable у-cells.
Tracer uptake was detected in grafts consisting of very low number of islets,
demonstrating the high sensitivity of the method.
Previously, imaging of liver islet transplants using 64Cu-labelled exendin has
been demonstrated in NOD/SCID mice [22]. Twelve days follow-up of the grafts 
revealed signiﬁcantly higher uptake of 64Cu-labeled exendin-4 in the liver of
transplanted animals when compared to the control group. Here, we used the skeletal 
muscle as a highly controlled model for histological veriﬁcation of insulin positive
area, which enabled us to reveal, for the ﬁrst time, an excellent linear correlation 
between the numbers of beta cells that were successfully engrafted, and the uptake 
of the tracer by the grafts.
Recently, it was reported that injection of 123I-IBZM enables the quantiﬁcation of 
BCM in islet grafts, where tracer uptake could be linearly correlated with graft volume 
[26, 27]. However, a far lower correlation was observed between 123I-IBZM uptake
and insulin volumes when compared to 111In-exendin, indicating that GLP-1R could 
allow more accurate assessments of islet graft survival. Exendin displays a much
higher uptake in the graft, allowing for detection of lower amounts of transplanted
islets. In addition, the higher uptake in the graft as compared to the low background 
leads to improved quantiﬁcation as a consequence of the better signal to noise ratio. 
Finally, our data indicate that 111In-exendin has an advanced detection sensitivity of 
islet grafts when compared to 123I-IBZM. In fact, more than 50% of the islets could be 
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lost in the ﬁrst days after transplantation [28], indicating that 111In-exendin-SPECT 
could detect grafts containing far less than the 50 islets being initially transplanted.
On the other hand, 123I-IBZM-SPECT was able to detect islets in a graft where
originally 1000 islets had been transplanted, indicating that grafts containing only low 
amounts of islets cannot be visualized as with exendin. The superior detection 
sensitivity of 111In-exendin-SPECT could be explained by the higher abundance of the 
GLP-1R on the surface of the beta cells when compared to the dopamine 2 receptor
[24, 26]. Hence, 111In-exendin-SPECT has the potential to detect small grafts that
underwent considerable beta cell loss, and could facilitate treatment assignment or
adaptation in order to preserve the remaining islets that could still exert a positive 
effect on glucose homeostasis. 
In summary, 111In-exendin-3 accumulation in islet grafts correlates linearly with 
living beta cells, and allows the detection of islet grafts consisting of less than 50 
islets by SPECT imaging. This indicates that this approach can successfully be
applied for accurate and sensitive quantiﬁcation of viable beta cells.
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Introduction
Islet transplantation is a promising experimental approach to reverse hyperglycemia 
in type 1 diabetic individuals [1]. However, a number of stress factors such as gluco/
lipo-toxicity, speciﬁc immune-assaults and instant blood-mediated inﬂammatory 
reaction (IBMIR) lead to decline in graft function and survival [2-5]. Current clinical 
tests cannot determine whether graft failure and relapse into hyperglycemia is caused 
by у-cell dysfunction or death [6, 7]. Non-invasive tools are, therefore, warranted to
determine BCM after transplantation, independently of graft function. Molecular
imaging has emerged as a promising tool to quantify BCM after speciﬁc targeting of 
у-cell surface markers. The glucagon-like peptide-1 receptor (GLP-1R) is an attractive 
biomarker which is speciﬁcally expressed on the у-cell surface and not in т, х and pp
cells [8]. In vivo targeting of the GLP1-R using 111In-exendin, followed by SPECT 
(Single Photon Emission Computed Tomography) was demonstrated as a promising 
strategy to visualize and quantify small differences in BCM in the pancreas of healthy
and diabetic individuals [9]. In addition, the GLP-1R can also be used as a target for 
BCM assessment in engrafted islets [10].
Islet transplantation is performed in subjects with long-standing history of brittle 
diabetes and with frequent episodes of hypoglycemia. Long-term exposure of у-cells
to hyperglycemia has a detrimental effect on their survival, replicative and functional
capacities [3, 11, 12]. In addition, it was reported that GLP-1R expression is down- 
regulated both in vitro and in vivo after long-term exposure of the у-cells to hyper-
glycemia [13-15]. Finally, the therapeutic effect of incretin-based pharmaceuticals on
type 2 diabetes patients (e.g. with the GLP-1 analogue, exenatide) is hampered by 
elevated blood glucose levels [16], while being more effective in patients with well-
regulated blood glucose levels [17]. These clinical observations could be explained
by, for instance, downregulation of the GLP-1R expression by the у-cells [13]. Hence, 
the effect of hyperglycemic stress on 111In-exendin uptake by the у-cells for BCM
quantiﬁcation should be assessed for determination of optimal protocols for in vivo
imaging of BCM by this method.
The aims of this study were to determine the effects of sustained hyperglycemia 
on 111In-exendin accumulation in islets transplanted in the skeletal muscle of diabetic
(alloxan-treated) mice and to determine if GLP-1R is a reliable biomarker to quantify
living у-cells during hyperglycemia and after establishing glycemic control.
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Research Design and Methods
Animals. Female C3H/HeNCrl mice (22–30 g) were purchased from Charles River 
(Calco, Itlay). All experiments were conducted in accordance with Radboud Univserity
guidelines and on humane care and use of laboratory animals.
Experimental groups. Mice were injected i.v. with 75 mg/kg of alloxan (Sigma, St Louis, 
MO, USA) as previously described [9]. Experiments started after hyperglycemia was 
conﬁrmed (25-30mmol/L) by using a glucose meter (Accu-Chek Sensor; Roche
Diagnostics; Almere, The Netherlands).
Mice assigned to the control group (group 1) received subcutaneous injection of 
insulin implants (LinShin, Toronto, Ontario, Canada) 7 days after alloxan injection (5-9
mmol/L) and were transplanted with islets after 14 days, where glycemic levels were 
stabilized for at least 5 days. SPECT imaging was performed 4 weeks after transplan-
tation. Mice assigned to the discontinued insulin-treatment group (group 2) were 
treated with insulin 7 days after alloxan injection, for a period of 14 days (5-9 mmol/L) 
prior to islet transplantation, and insulin pellets were surgically removed 14 days after
transplantation to re-induce hyperglycemia (5-9mmol/L then 24-30 mmol/L). SPECT 
imaging was performed after 4 weeks of hyperglycemia. Mice assigned to the insu-
lin-treated group (group 3) were treated with insulin 7 days after alloxan injection, for
a period of 14 days (5-9 mmol/L) prior to islet transplantation, and insulin pellets were 
surgically removed 14 days after transplantation to re-induce hyperglycemia (24-30
mmol/L). Finally, mice were re-treated with insulin pellets to re-establish normoglycemia 
(5-9mmol/L). SPECT imaging was performed after 2 weeks of normoglycemia.
Islet isolation and transplantation. Pancreatic islets were isolated from 8 weeks-old
female C3H/HeNCrl donor mice by collagenase digestion method and recipients 
were transplanted with 200 islets in the calf muscle as previously described [10].
Number of transplanted islets was determined as insufﬁcient to reverse hyperglycemia.
Radiolabeling. [Lys40(DTPA)]-exendin-3 was purchased from Peptide Specialty 
Laboratories (Heidelberg, Germany). Radiolabeling procedure was performed as
previously described [9]. Radiochemical purity was evaluated by ITLC and the 
radiolabel was puriﬁed by solid-phase extraction using a HLB-cartridge (Waters, 
Etten-Leur, The Netherlands) before animal injection [9]. Animals were injected with 
0.1 μg of exendin-3 radiolabeled with approximately 15 MBq in a 0.5% bovine serum 
albumin solution in 200 μl phosphate-buffered saline.
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Imaging procedure and data acquisition. All mice were scanned 1 hour post
injection of 111In-exendin. Scans were performed with a small animal U-SPECT-II/CT
system (MILabs, Utrecht, The Netherlands) using a 1 mm multi-pinhole ultra-high 
sensitivity mouse collimator for 50 minutes. Groups 1 and 2 were scanned 4 weeks
after transplantation and group 3 was scanned 6 weeks after transplantation. CT 
scans were performed in full/accurate mode under 615 μA/s and 65 kV. After SPECT/
CT acquisitions, animals were euthanized and calf muscles containing the transplant 
were extracted and incubated in 1% paraformaldehyde inside eppendorf tubes where 
ex vivo scans were acquired for 12 hours. SPECT data were reconstructed using
OSEM (3 iterations, 16 subsets, voxel size 0.4 mm) with the U-SPECT-Rec software 
(MILabs, Utrecht, The Netherlands). To quantify SPECT signal, a volume of interest
(VOI) was drawn in the area of the transplant and the background was subtracted 
after applying similar VOI on contra-lateral calf muscle that did not contain islets. 
Data were corrected for the injected dose and converted to kBq by using standards 
with known activity scanned and reconstructed under similar settings.
Immunohistochemistry. For autoradiography, muscles containing the transplant 
were embedded in parafﬁn and 4 μm thick sections were cut at separate levels of the 
tissue with 40 μm distance. Muscle sections were exposed to an imaging plate (Fuji 
Film BAS-SE 2025, Raytest, Straubenhardt, Germany) for one week. Images were
visualized with a radioluminography laser imager (Fuji Film BAS 1800 II system,
Raytest, Straubenhardt, Germany). Quantiﬁcation of the autoradiographical images
was performed with AIDA Image Analyzer software (Raytest GmbH, Straubenstadt, 
Germany). Radioactivity accumulation in the transplants was measured by drawing 
ROIs around each transplant as well as around the standards with known amount of 
radioactivity. For measurement of insulin area in the autoradiography corresponding
transplants, sections were processed for antigen retrieval by incubating in 10 mM
citrate pH 6 for 10 min at 96 °C and blocked with 1% BSA (w/v in PBS) for 30 min and
endogenous peroxidase activity was blocked with 3% H2O2 (v/v in PBS) for 30 min.
Staining was performed with anti-insulin rabbit antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) diluted 1/50 during 1 hour at room temperature. Sections were
next incubated with swine anti-rabbit conjugated with peroxidase, during 30 min at 
room temperature and washed with PBS. Finally, hematoxylin counterstaining was 
performed and sections were visualized by bright ﬁeld microscopy (Leica Micro-
systems, Wetzlar, Germany). Autoradiography data was normalized by the insulin 
area measured in the corresponding section and was expressed in Bq (Becquerel).
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Results
Islet transplants can be detected with 111In-exendin-3 and SPECT during hyper- 
glycemia and after restoring normoglycemia. To determine whether islet transplants
can be detected during severe hyperglycemia and after insulin treatment, group 1
(control), group 2 (discontinued insulin-treatment) and group 3 (insulin-treated) were
injected with 111In-exendin and were scanned under the same parameters. Islets 
were detected in all groups of mice (ﬁgure 1 A-C). SPECT signal was lower in
recipients that were scanned after prolonged periods of hyperglycemia. On the other
hand, SPECT signal was higher after insulin treatment.
Blood glucose levels inﬂuence 111In-exendin-3 accumulation in islet transplants.
In order to determine the effect of blood glucose levels on 111In-exendin-3 accumulation
in islet transplants, we performed ex vivo autoradiography on muscle sections 
containing the islets, followed by insulin staining (ﬁgure 2A-C). There was accumulation
of 111In-exendin-3 within well-localized regions of the muscle in all groups of mice,
which was in co-localization with insulin staining.
Figure 1  SPECT imaging of islet transplants with 111In-exendin.
(A) SPECT imaging detected islet grafts in group 1. (B) SPECT signal was decreased after four
weeks of hyperglycemia (group 2). (C) Tracer uptake has recovered after insulin treatment 
(group 3).
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Quantiﬁcation of tracer accumulation in islet grafts revealed lower tracer uptake per 
insulin area after a severe and prolonged period of hyperglycemia, when compared
to the control group (ﬁgure 2D). Importantly, after 2 weeks of continuous insulin 
treatment, tracer uptake was restored and became comparable to the control group. 
Linear correlation between insulin area and exendin-3 uptake was observed for all 
groups of mice. 
Similarly, tracer uptake in the pancreas of the recipients was signiﬁcantly decreased
by elevated blood glucose levels and was restored after insulin treatment (ﬁgure 3).
Figure 2 111In-exendin uptake by islet grafts is affected by blood glucose levels. 
Autoradiography analysis and insulin staining showed co-localization between exendin uptake
and у-cells, in (A) group 1, (B) group 2 and (C) group 3. (D) Quantitative analysis of autoradiog-
raphy revealed linear correlation between tracer uptake and insulin areas in all groups of mice, 
while tracer uptake per insulin area was decreased in group 2 when compared to group 1 and 
3. Colored area around the linear regression represent the conﬁdence intervals (p<0.95).
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Discussion
In the present study, we examined the effect of glycemia on the uptake of 111In-
exendin-3 by islet transplants. We demonstrated that increased blood glucose levels 
2 weeks after transplantation results in decreased accumulation of 111In-exendin-3 in 
the transplant. Restoring of blood glucose control for a period of 2 weeks, subsequent
to 4 weeks of hyperglycemia, restores the level of tracer uptake by the islets. These 
results indicate that blood glucose levels have a direct inﬂuence on BCM quantiﬁcation 
and must be considered when measuring islet graft survival. Imaging of islet 
transplants with radiolabeled exendin will reveal reliable results when normoglycemia
is achieved 2 weeks prior to targeting of the islets with radiolabeled exendin.
Detection of islet grafts with SPECT was feasible during normoglycemia, as well 
as hyperglycemia. Autoradiography-based analysis of islet sections revealed that
changes in SPECT signal were not due to changes in BCM, given the differences in
tracer uptake per insulin-positive area. Decreased tracer accumulation in the islets
during hyperglycemia is in accordance with clinical observations, where type 2
diabetes patients exhibit an impaired response to incretin-based treatments [13, 16].
Figure 3  Biodistribution of 111In-exendin in control, hyperglycemic and insulin-
treated groups.
111In-exendin uptake was observed in organs known to express the GLP-1R in all groups of 
mice. Tracer accumulation was decreased during hyperglycemia, and increased after insulin
treatment in the exendin-targeted organs.
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Several processes could explain the decrease in exendin-3 uptake by the beta cells 
during hyperglycemia. One possibility is down-regulation of GLP-1R expression by 
the beta cells. Another possibility is, that exendin-3 internalization after binding to
GLP-1R is hampered due to changes in the downstream signaling systems [14], 
causing less efﬁcient trapping of the tracer inside the beta cells [18]. Finally, the effect 
of prolonged hyperglycemia on decreasing intra-islet blood ﬂow could result in 
impaired delivery of the radiotracer to the islets [19]. Restoration of tracer uptake by 
the islets after achieving normoglycemia indicates that the mechanisms involved in 
this process are reversible. This is in accordance with clinical observations, where
type 2 diabetes patients with well-regulated blood glucose levels have an effective 
response to incretin actions [13, 16, 17].
In line with previous study [20], tracer uptake allowed to determine the BCM in 
healthy islet recipients. We also observed a linear correlation between BCM and
tracer uptake during hyperglycemia, despite the decreased uptake per insulin area. 
As we do not know whether there is a threshold for hyperglycemia to cause reduction 
of exendin uptake, we believe that exendin scans should be performed under 
euglycemic conditions or at least, under comparable glycemic conditions, the latter 
potentially leading to higher patient numbers required for inter-individual comparison 
in clinical studies.
It was demonstrated that exendin-3 uptake in the pancreas allows to detect small
differences in the BCM between healthy and diabetic subjects [9]. Here, uptake in 
the pancreas (as well as in islet transplants) was decreased by hyperglycemia, as 
compared to the insulin-treated group, and was restored after 2 weeks of normo-
glycemia. We therefore suggest that normoglycemia should be achieved prior to 
BCM quantiﬁcation with 111In-exendin. 
In conclusion, this study reveals that blood glucose level is a key physiological 
parameter to consider when quantifying BCM by in vivo targeting of the GLP-1R with
111In-exendin-3. Reliable quantiﬁcation of BCM using exendin-3 can be achieved 2 
weeks after restoring normoglycemia, where tracer uptake is no longer affected by 
beta cell hyperglycemic stress.
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Abstract
In-vivo targeting of the GLP1-R with 111In-exendin-3 followed by Single Photon 
Emission Computed Tomography (SPECT) has become a promising experimental 
approach to monitor changes in у-cell mass (BCM) during diabetes progression.
SPECT imaging of pancreatic islets is most commonly cross-validated by stereological 
analysis of histological pancreatic slices subsequent to insulin staining. Typically,
stereological methods do not accurately determine the total у-cell volume, which is 
inconvenient when correlating total pancreatic tracer uptake with BCM. Alternative 
methods are therefore warranted to cross-validate у-cell imaging using radiotracers. 
Here, we evaluated optical projection tomography (OPT), a technique that provides
3-D quantitative imaging of the pancreatic islets, for cross-validating radionu-
clide-based imaging of у-cells. Uptake of 111In-exendin-3 was measured by SPECT 
and was correlated with histology as well as OPT-based quantiﬁcation of insulin
positive areas within healthy and alloxan-treated Brown Norway rat pancreata. SPECT
signal was in excellent linear correlation with OPT data as compared to histology.
While histological determination of islet spatial distribution was challenging, SPECT 
and OPT revealed similar distribution patterns of 111In-exendin and у-cell distribution
across the pancreas. Here, we introduce SPECT-OPT multimodal imaging as highly 
accurate strategy for validating the performance of у-cell radiotracers.
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Introduction
The prevalence of diabetes is 415 million worldwide and the numbers are on the rise 
[1]. Both у-cell dysfunction and death contribute to diabetes progression. The
relationship between у-cell mass (BCM) and function is not clear and therefore, the 
routine immunological and functional tests are not suitable to monitor changes in 
BCM [2-4] . There is a high interest in developing non-invasive tools to quantify BCM, 
independently of their function, to better understand the progress of the disease. 
Current non-invasive imaging techniques, with the highest anatomic resolution 
available, are not powerful enough to detect single islets in vivo and in humans at this 
point in time. Alternatively, radioactive-based imaging methods are used for their 
advanced detection sensitivity of tracer uptake by у-cells [5, 6]. Speciﬁc targeting
of у-cells by 111In-exendin-3 followed by SPECT was reported as a promising tool
to detect and quantify small differences in BCM in T1D rodent models as well as 
T1D patients [7]. These ﬁndings were validated by the linear correlation between 
111In-exendin uptake and histological quantitative analysis of BCM in rodents.
Although comparison between radioactive imaging and two-dimensional stereo- 
logical techniques is a conventional research practice, which beneﬁts from the 
possibility to correlate tracer uptake with the quantiﬁcation of insulin producing у-cells
at (sub-)cellular resolution, such a method is associated with several disadvantages.
Typically, stereological techniques rely on certain assumptions, in particular regarding 
the degree of convexity of the islets and their orientation/distribution within the gland,
to estimate islet уcell volume or mass. In addition, such techniques are highly labor 
and time consuming and are, consequently, performed by interval or random sampling, 
even for limited cohorts of animals. Therefore, the outcome will inevitably be an 
extrapolation of two-dimensional information. It has been demonstrated that the islet
уcells are differing in size and are heterogeneously distributed within the organ, both 
with respect to the individual lobular compartments and between the lobes [8, 9].
In addition, different regions of the pancreas could be unequally affected by diabetes 
in different animals of the same strain and stage [10], further complicating the picture. 
Hence, sampling techniques are, depending on the analyzed model, prone to over- 
or underestimate the true BCM, and are largely dependent on the chosen quantiﬁcation 
method. Indeed, the establishment of a stereological approach to describe the complete
pancreatic islet-volume distribution has been described as a “true stereological
challenge” [11]. Consequently, an alternative strategy to correlate radiotracer uptake 
in the pancreas with actual BCM is needed.
Previous studies developed an OPT-based method that allows visualizing and
studying ﬁxated biological specimens at high spatial resolution [12]. This technique 
was shown remarkably accurate for quantifying BCM and determining the spatial 
distribution within and between the lobes of the pancreas down to the resolution of 
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single islets after ex-vivo antibody-based targeting of insulin [8, 9, 13]. Importantly,
OPT allows to scan a sample with high resolution on the millimeter to centimeter-scale
[14], thereby being a technique of choice to image complete lobes of murine pancreas
[8, 13].
Here, we sought to determine whether fast and accurate cross-validation of 
radionuclide-based imaging of у-cells can be achieved by sequential SPECT-OPT
multimodal imaging, as compared to SPECT followed by histology. Uptake of 111In
labeled [Lys40(DTPA)6]-exendin-3 by the у-cells was quantiﬁed by SPECT and was
cross-examined by histology and OPT-based assessment of insulin volume in the 
splenic, gastric and duodenal lobes [14] of healthy and alloxan-treated diabetic of
Brown Norway (BN) rats.
Research Design and Methods
Animals and alloxan treatment. Female Brown Norway rats (110-120 g) were purchased
from Charles River (Calco, Itlay). All experiments were conducted in accordance with
Radboud Univserity and Umeå University guidelines on use of laboratory animals. 
Experiments were approved by the Animal Ethical Committee of the Radboud University,
Nijmegen, The Netherlands and the Ethical Committee for Animal Research, Northern
Sweden. Rats assigned to the diabetic group were injected intravenously with 60 mg/
kg of alloxan (Sigma, St Louis, MO, USA) as previously described [7] and animals
assigned to the healthy group were injected with the vehicle compound. Experiments 
started after conﬁrmation of hyperglycemia (>20mmol/L) in alloxan-treated rats by using
a glucose meter (Accu-Chek Sensor; Roche Diagnostics; Almere, The Netherlands), 
namely 7 days after the injection.
Radiolabeling of exendin-3. [Lys40(DTPA)6]-exendin-3 was purchased from Peptide
Specialty Laboratories (Heidelberg, Germany). Peptide labeling with In-111 and quality
controls were performed as previously described [7]. All animals were injected with
20pmol of exendin-3 corresponding to approximately 150 MBq.
SPECT imaging and data acquisition. Rats were intravenously injected with
radio-labeled exendin-3 and euthanized 1 hour post-injection. The pancreata were 
isolated and the splenic, gastric and duodenal lobes were separated. Finally, lobes
were ﬁxed in 4% PFA for two hours and were scanned in phosphate buffered saline
(PBS) with the small animal U-SPECT-II/CT system (MILabs, Utrecht, The Netherlands) 
with a 0.2 mm multi-pinhole collimator for 12 hours. Images were reconstructed with
OSEM (3 iterations, 16 subsets, voxel size 2 mm) using the U-SPECT-Rec software
(MILabs, Utrecht, The Netherlands) and the measured counts were converted to kBq
(Kilobecquerels) using standards with known radioactivity concentrations scanned
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with the same settings. After SPECT acquisitions, lobes were measured for 
radioactivity in a ф-counter (Wallac 1480 Wizard, Perkin Elmer, Boston, MA, USA) and
data were expressed as the percentage of administered dose.
OPT imaging and data acquisition. After quantiﬁcation of radioactivity, pancreata
were stepwise dehydrated in 33%, 66% and 100 % methanol and stored at -20°C.
Tissue samples were next stained for Insulin (Primary antibody Guinea Pig anti-insulin,
(DAKO: A0564) and secondary antibody IRDye 680 anti-Guinea Pig (Licor:
926-68077)) and processed for OPT imaging essentially as described previously 
[13]. OPT scans were performed for individual lobes using a Near Infrared-OPT
(NIR-OPT) setup with excitation ﬁlter 665/45 and emission ﬁlter 725/50 as described
previously [13]. The anatomy of the pancreas, based on its auto-ﬂuorescence, was
obtained by scanning it with a excitation 480/40 and emission 510LP ﬁlter set.
Tomographic reconstruction was performed essentially as described [13]. Contrast 
limited adaptive histogram equalization (CLAHE) was not needed due to a good 
signal to noise ratio obtained in volume rendering data. Insulin stained у cell volume 
was quantiﬁed by generating 3D iso-surface based on signals from individual islets 
using Imaris 7.7. software (Bitplane).
Immunohistochemistry and morphometric analysis. Following OPT scans, the
specimens were treated with methanol 4-5 times (for 3-4 days) and were rehydrated
with 70%, 50%, 30% and 10% ethanol. Excess of agarose was trimmed off when the 
samples were in 10% ethanol and then incubated in 0.29 M sucrose for 60 min at 
room temperature followed by incubation in preheated 0.29 M sucrose at 57 °C to
completely remove residual agarose and washed in PBS. Next, the pancreata were 
subjected to parafﬁn embedding and 4 μm thick sections were produced at 3 
separate levels of the tissue with 100 μm distance. Sections were submitted for
antigen retrieval during 10 min in 10 mM citrate pH 6 at 96°C and blocked with 1% 
BSA in PBS for 30 minutes and endogenous peroxidase activity was blocked with 3% 
H2O2 in PBS for 30 minutes. Staining was performed using anti-insulin rabbit antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1/50 for 1 hour at room 
temperature and washed in PBS. Sections were next incubated with swine anti-rabbit 
conjugated with peroxidase, for 30 min at room temperature and washed with PBS.
Finally, hematoxylin counterstaining was performed and sections were scanned with
Pannoramic250 Flash II scanner (Budapest, Hungary). BCM was next estimated by 
measuring the average of insulin staining areas of 3 sections per lobe (expressed in 
μm2) separated by 100 μm. The quantiﬁcation was performed using Adobe Photoshop 
CS5 Version 12.0.
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Statistical analysis. Values are expressed as means ± SEM. Student t-test was
performed for comparisons, where P value <0.05 was considered as statistically
signiﬁcant. To assess whether the correlation of SPECT-OPT and SPECT-histology
differs, comparisons were performed using multiple linear regression analysis
(ANCOVA). All statistical tests were performed with Graphpad Prism 5 (GraphPad
Software, San Diego California USA).
Results
Correlation of SPECT imaging with morphometric determination of BCM. 111In-
exendin-3 uptake was quantiﬁed by SPECT imaging of single pancreatic lobes from 
healthy and diabetic animals, and the accuracy of the measurements was veriﬁed by 
the linear correlation between SPECT data and gamma-counter based analysis of 
radioactivity (r2=0.85) (Supplementary Figure S1 A). Healthy rats showed higher 
accumulation of radioactivity (measured by gamma-counter) per gram of pancreatic 
tissue when compared to the diabetic group (Supplementary Figure S2 A).
Morphometric analysis of insulin staining was conducted at three different levels 
of each pancreatic lobe (Figure 1A-B). Insulin stained BCM (mg) in alloxan treated 
pancreata was signiﬁcantly reduced to 7.94% in comparison with the healthy group 
(p<0.001) (Figure 1C). Spatial quantitative analysis of у-cells did not show any
signiﬁcant differences in their distribution between the pancreatic lobes (Figure 1D).
In line with our previous studies [7], we observed a linear correlation between 111In-
exendin-3 uptake and insulin positive area per lobe (r2= 0.52) (Figure 1E). Similarly, a 
linear correlation was observed between SPECT and histological based analysis of
total BCM (r2=0.53) (Supplementary Figure S1 B).
Multimodal imaging of rat pancreatic lobes with SPECT and OPT. High uptake of
111In-exendin-3 was observed by SPECT in the pancreas of healthy rats (Figure 2A).
This was in line with the abundant insulin staining visualized by OPT (Figure 2C). Rats
that were treated with alloxan prior to SPECT and OPT imaging exhibited decreased 
signal by both modalities (Figure 2B and D). Furthermore, the distribution of 111In-
exendin-3 accumulation was similar to the distribution of the у-cells observed by 
OPT. Quantiﬁcation of 111In-exendin-3 uptake showed an accumulation of 55.46 ± 
5.55 kBq in the pancreas and a total у-cell volume of 1.18x1010 ± 1.11x109 μm3 (Figure
3A-B). Quantitative analysis of alloxan-treated rats showed a signiﬁcant decrease in
BCM (p<0.001), where uptake of 111In-exendin-3 (17.27 ± 2.04 kBq) and у-cell 
volume (3.13x109 ± 7.17x108 μm3) dropped to 23% and 26.5%, respectively, when 
compared to the healthy group. Quantiﬁcation of 111In-exendin-3 uptake in splenic, 
gastric and duodenal lobes, showed inhomogeneous distribution of 111In-exendin-3 
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uptake.
(A, B) Representative images of insulin positive areas in control (A) and alloxan treated (B) rats.
(C) Bar chart displaying BCM (mg) (n=5). (D) Graph displaying quantitative analysis of у-cell 
inter-lobular distribution (n=4-5). (E) BCM (mg) was plotted against 111In-exendin-3 uptake
(kBq, kilobecquerels) as determined by SPECT (r2=0.52, p=8.13 x 10-06). In (A-E) untreated 
rats are shown in black and alloxan-treated rats are shown in white. Data are shown as means
± SEM, where *p<0.05, **p<0.01 and ***p<0.001 compared with the corresponding healthy 
group. Scale bar represents 100 μm.
A
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accumulation between the lobes, as the uptake was 22.06 ± 1.48, 10.58 ± 2.72 and 
14.57 ± 2.55 kBq, respectively (Figure 3C). A similar distribution pattern was observed 
by OPT, where у-cell volume in splenic, gastric and duodenal lobes was equal to
4.90x109 ± 5.81x108, 3.14x109 ± 6.72x108 and 3.61x109 ± 6.25x108 μm3, respectively 
(Figure 3D). Alloxan treatment resulted in decreased exendin uptake (measured by
SPECT) and у-cell volumes (measured by OPT) in all lobes. The linear correlation (r2)
between exendin-3 uptake and у-cell volume per lobe was 0.77 (Figure 3E), and for 
total BCM 0.81 (Supplementary Figure S1 C).
Figure 2  Multimodal imaging of pancreatic у-cells with SPECT and OPT.
(A, B) Ex vivo SPECT scans of representative splenic lobes from a healthy (A) and an alloxan
treated animal (B) respectively. (C, D) OPT generated iso-surface images of the same lobes as
visualized in (A, B). Alloxan-treated rats exhibit lower 111In-exendin-3 uptake and у-cell volume
when compared to the control group. Scale bar represents 3 mm.
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Figure 3  SPECT based radioactive quantiﬁcation of 111In-exendin-3 uptake 
correlates with OPT based quantiﬁcation of insulin positive у-cell volume.
(A, B) Quantiﬁcation of absolute 111In-exendin-3 uptake (kBq) by SPECT (A) and total у-cell 
volume (μm3) by OPT (B) (n=5). (C, D) Graphs illustrating the heterogeneous distribution of
у-cells between the splenic (SL), gastric (GL) and duodenal lobes (DL) as determined by
SPECT (C) and OPT (D) respectively (n=4-5). (E) Graph showing pancreatic uptake of 
111In-exendin-3 by separate lobes plotted against у-cell volume shows a strong correlation
(r2=0.77, p=2.07 x 10-10). In (A-E) untreated rats are shown in black and alloxan-treated rats are
shown in white. Data are shown as means ± SEM, where *p<0.05, **p<0.01 and ***p<0.001
compared with the corresponding healthy group.
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Importantly, SPECT data was successfully compared with OPT analysis of the entire 
islet population of each pancreas within a time period during which only a limited 
number of intervallic sections per lobe could be analyzed by stereology. Furthermore,
SPECT-OPT correlation (r2=0.77) was signiﬁcantly superior to SPECT-histology 
(r2=0.52) (p<0.001). There were no signiﬁcant differences between the linear regression
slopes (p=0.82) (Supplementary Figure S2 B).
Discussion
In the present study, we examined the utility of SPECT-OPT multimodal imaging for
fast and accurate validation of radionuclide-based imaging of у-cells. The successful 
imaging of у-cells by SPECT and OPT, respectively, demonstrated the possibility of 
combining the protocols of both imaging modalities. 111In-exendin-3 uptake and 
insulin volume as measured by SPECT and OPT were in excellent linear correlation, 
demonstrating that the performance of у-cell radiotracers can be cross-examined by
OPT. Decreased OPT signal subsequent to alloxan treatment was in line with SPECT 
signal, further demonstrating that the data generated using OPT are consistent with
measurements obtained by SPECT.
While the resolution provided by conventional microscopy prevails over OPT,
correlation of insulin staining with exendin-3 uptake by immunohistochemical analysis 
was signiﬁcantly lower, indicating that stereological methods may be less accurate 
than OPT for validating SPECT-based quantiﬁcation of BCM, mainly because they 
are prone to BCM quantiﬁcation errors. Including more histological sections into
the quantitative analysis for each lobe would be expected to increase the BCM
quantiﬁcation accuracy, but would also be more labor and time-consuming. In contrast, 
excellent linear correlation was achieved in a similar period of time, by combining 
SPECT and OPT imaging, where quantiﬁcation of tracer uptake was followed by a 
single acquisition of the entire insulin positive cell population of intact pancreatic
lobes [8], thus comparing three-dimensional data sets.
Assessment of islet spatial heterogeneity with histology was challenging, given
the two-dimensional aspect of the method. On the other hand, inhomogeneous
distribution of the islets between the pancreatic lobes was evident by SPECT and 
OPT. The splenic lobe harbored the largest BCM, followed by the duodenal and the
gastric lobes respectively, which is in agreement with the у-cell distribution previously 
recorded for the murine pancreas [9]. Furthermore, the distribution of 111In-exendin-3
in alloxan treated pancreata was, not only quantitatively, but also visually in agreement
with OPT (ﬁgure 1). Residual у-cells in alloxan-treated rats were mainly observable in 
the core of the lobes, an area also showing the highest accumulation of 111In-exendin-3. 
The excellent correspondence between SPECT and OPT spatial information endorses
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the previously reported radiotracer speciﬁcity towards the у-cells [7]. Therefore, 
SPECT-OPT multimodal imaging allows validation of radiotracer biodistribution in the 
pancreas, including information with respect to у-cell spatial heterogeneity, which 
renders this methodology highly convenient when validating established radiotracers 
and evaluating the speciﬁcity and performance of novel у-cell radiotracers.
In conclusion, we report the successful multimodal imaging of pancreatic islets
after coupling protocols from two independent approaches, into one that combines
radionuclide and optical imaging of у-cells. Excellent correlation between 111In-exendin
uptake and insulin volume was obtained by SPECT-OPT, when compared to SPECT
followed by histology, demonstrating that this new strategy may be more reliable in
validating the actual performance of у-cell radiotracers. In addition, as compared to 
morphometric analysis of pancreatic sections, OPT is highly time-efﬁcient.
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Supplemental data
Figure S1  Linear correlations between 111In-exendin-3 uptake and BCM.
(A) Correlation of SPECT data (kBq) with gamma-counter analysis (%ID, percentage of injected 
dose) of separate pancreatic lobes (r2=0.85, p=5.55x10-12) (n=15). (B, C) graphs showing 
total pancreatic uptake of 111In-exendin-3 (SPECT) plotted against total BCM (histology)
(r2=0.53, p=0.017) and total pancreatic у-cell volume (OPT) (r2=0.81, p=0.0004) respectively
(n=5).
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Figure S2 Alloxan treated rats display a signiﬁcantly reduced uptake of 
111In-exendin-3.
(A) The Graph illustrates the pancreatic uptake of radioactivity normalized by the weight of the
pancreas (%ID/g, percentage of injected dose per gram) of healthy control animals and alloxan
treated animals as measured by gamma-counter. (B) Two-way dependent correlation coefﬁcients 
comparison (SPECT-OPT r2=0.77, SPECT-histology r2=0.52; n=30) reveals signiﬁcant differences
between SPECT-OPT and SPECT-histology correlations (p<0.001). ANCOVA analysis reveals 
no signiﬁcant differences between SPECT-OPT and SPECT-histology linear regression slopes
(p=0.82). Data are expressed in relation to (%) the highest BCM value measured in a lobe by 
the corresponding modality.
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1. Use of 111In-exendin for effective and non-invasive 
quantification of BCM in transplanted islets
Transplantation of islets of Langerhans is an innovative experimental approach to 
reverse hyperglycemia in patients with long history of type 1 diabetes and with frequent
episodes of hypoglycemia [1]. To date, the number of recipients that remain insulin
independent 5 years after transplantation is as low as 15% and the current clinical 
tests cannot determine if graft failure originates from у-cell loss or decline in function 
[2]. Non-invasive imaging is therefore needed to quantify the number of living у-cells.
Quantiﬁcation of pancreatic BCM by SPECT imaging with 111In-exendin was 
previously achieved in a rat model for diabetes, as well as in healthy and diabetic
subjects, and might be useful to detect у-cell loss [3]. The main objective of the
studies described in this thesis was to characterize 111In-exendin imaging strategy to 
quantify BCM which could help improving the outcome of islet transplantation.
Islet isolation disrupts the blood vessels between the islets and the surrounding 
tissue, which, depending on the transplantation site, would require several weeks to
be completely restored. In Chapter 3, we demonstrated that disruption of the islet
vasculature from the surrounding tissue after isolation, has great inﬂuence on the 
radiotracer targeting properties towards the islets, and BCM quantiﬁcation using 
111In-exendin. Revascularization progress in the graft improves radiotracer uptake in 
the islets. Complete restoration of islet vasculature in the transplant allows reproducible 
accumulation of 111In-exendin in the graft, for reproducible quantitative imaging of the 
islets, 4 weeks after transplantation. In Chapter 4, injection of 111In-exendin, 4 weeks 
after transplantation, in recipients that received different amounts of islets allowed to
quantify BCM with high accuracy and with high sensitivity. In particular, a linear 
correlation was observed between SPECT signal of 111In-exendin uptake and the
amount of у-cells that were successfully engrafted. Detection and accurate
quantiﬁcation of BCM was even achievable in recipients that were injected with an 
initial amount of 50 islets.
Stable expression of the GLP-1R is required for reliable quantiﬁcation of the BCM. 
Under homeostatic blood glucose levels, GLP-1R expression is expected to be stable,
allowing reliable quantiﬁcation of the BCM. However, it was previously demonstrated 
that chronic exposure to hyperglycemia leads to downregulation of the GLP-1R
in pancreatic у-cells [4]. This could inﬂuence radiotracer uptake by the graft, and 
consequently, inﬂuencing the imaging results, which leads to erroneous quantiﬁcation
of the actual BCM. In Chapter 5, we demonstrated that 111In-exendin uptake in islet 
grafts is inﬂuenced by changes in blood glucose levels. Elevated blood glucose 
levels lead to decrease in tracer accumulation in the graft. Re-establishment of normal
glycemic levels restored tracer uptake in the graft, indicating the direct inﬂuence of 
glycemia on quantiﬁcation of BCM.
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Determination of BCM was based on a stereological approach, where у-cell areas in
graft micro-sections were extrapolated to 3D data of complete graft volumes. For
accurate determination of graft volumes, it was therefore necessary to section the 
entire muscle tissue. In Chapter 6, an alternative method was suggested, in the 
pancreas, where BCM could be easily determined, without requiring the sectioning of 
a complete organ: We have used OPT as a reliable alternative to histology to validate 
exendin-based quantiﬁcation of BCM. The method allowed visualizing the entire 
у-cell population of a pancreas in a single acquisition and with high accuracy when 
compared to histology.
2.  Implications and future perspectives
Use of radiolabeled exendin for monitoring of islet grafts has an excellent clinical 
potential: (1) radiolabeled-exendin is clinically approved, which facilitates its clinical
implementation in the context of islet graft imaging. (2) The radiotracer successfully 
detects islet grafts in transplantation sites that are clinically relevant (i.e. the liver) or 
in skeletal muscle [5, 6].
Delivery of radiotracers to transplanted islets – Tracer uptake by islet grafts depends 
on the speed of recovery of islet vasculature, which has signiﬁcant implications on
BCM quantiﬁcation. Several factors could affect the delivery of radiotracers and the
time-point after which intra-islet vasculature is restored: (1) Different organs inherently 
have different angiogenic potential. Typically, the skeletal muscle has different 
angiogenic potential, when compared to other known transplantation sites, such as 
the interior chamber of the eye and the liver [7, 8]. As a result, vascular density in the
islet graft could differ between different sites, which could have a direct inﬂuence on 
the amount of radiotracers that accumulate in the islets. Interestingly, tracer uptake
was detected as early as 3 days after transplantation, where vascular density was
very low. (2) Angiogenesis might be suboptimal in recipients with long-history of 
diabetes, which could inﬂuence the amount of radiotracers accumulating in the graft. 
(3) Changes in the blood ﬂow; We observed that diabetic islet-recipients that 
underwent severe and long-standing episode of hyperglycemia, and received insulin
treatments prior to injection of 111In-exendin, had higher tracer accumulation in the
graft when compared to diabetic recipients that received no insulin treatments. Graft 
revascularization is completed 4 weeks after transplantation and therefore, changes
in tracer uptake could potentially be explained by changes in blood ﬂow, which is 
decreased during hyperglycemia. Hyperglycemia could also affect tracer uptake
through other players stated below.
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Quantiﬁcation of BCM in islet grafts – 111In-exendin allows visualization of grafts
containing less than 50 islets in small animal models, indicating high sensitivity for 
detection of even a small beta cell mass. Exendin-SPECT imaging could therefore
allow highly sensitive detection of small grafts that underwent severe у-cell loss, and 
in this way, might facilitate treatment assignment or adaptation in order to preserve
remaining islets that could still exert a positive effect on glucose homeostasis. Such 
advanced sensitivity was not achieved by other у-cell markers currently under 
investigation, e.g. 123I-IBZM [9].
Pre-labeling of islet transplants with SPIOs-MRI showed promising results for
quantiﬁcation of islet graft volume in humans. However, a standardized labeling
protocol is needed and therefore a quantitative method is still missing. Furthermore, 
islet labeling does not allow to visualize the у-cells speciﬁcally, which is inconvenient 
when quantiﬁcation of BCM is desired. Clearly, the advanced detection sensitivity 
and the speciﬁc quantiﬁcation of у-cells by exendin-SPECT will be of great value for
human applications in the future.
It was previously demonstrated that у-cell loss can be detected with 111In-exendin-
SPECT. Whether this strategy allows to follow-up changes in BCM over-time after 
multiple injections of 111In-exendin must be evaluated in future studies.
Imaging the GLP-1R during diabetes – Reduced accumulation of 111In-exendin in 
islet transplants was evident after long exposure to severe hyperglycemia. Decreased 
exendin-3 uptake in the graft during hyperglycemia is in line with clinical observations,
where hyperglycemia contributes to impaired action of incretins on the beta cells in
type 2 diabetes patients [10]. One possible explanation for reduced radiotracer
uptake is downregulation of the GLP-1R [11]. Another possibility, is that exendin-3 
internalization after binding to the GLP-1R is hampered by changes in the downstream 
signaling pathways, causing less efﬁcient trapping of the tracer inside the beta cells
[12]. Reversal of hyperglycemia with insulin injections restored tracer uptake in the
graft, which could be explained by the recovery of GLP-1R expression and/or the
downstream internalization pathways of the receptor. Overall, normoglycemia should
be achieved prior to imaging of the GLP-1R, in order to alleviate у-cell stress and for 
reliable quantiﬁcation of BCM.
Novel approach for validating beta cell radiotracers – We have described OPT as 
a reliable alternative to histology to validate exendin-based quantiﬁcation of BCM. 
The method allowed visualizing the entire у-cell population of a pancreas in a single 
acquisition and with high accuracy when compared to histology. Whether OPT would 
be an alternative to histology for validating 111In-exendin imaging of islet transplants 
must be addressed in future studies. Interestingly, OPT was previously used to 
quantify BCM of islets transplanted in the liver [13], a transplantation site that is
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clinically relevant and which will take part of our future work to validate islet graft
imaging with 111In-exendin.
In conclusion, we characterized a method for non-invasive monitoring of trans- 
planted islets using 111In-exendin followed by SPECT imaging. Our strategy could 
potentially quantify graft survival, and in combination with у-cell functional tests, 
could provide clinicians with a comprehensive information about islet graft quality.
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Summary
The objective of the studies in the present thesis was to characterize the GLP-1R as a
potential target to visualize and determine the survival of transplanted islets in vivo. 
Chapter 2 provides an overview of the strategies that are used in nuclear medicine
to visualize and quantify BCM of islet transplants and the animal models that can be
used to characterize and validate new у-cell radiotracers. Several strategies were
exploited over the last decade to visualize and quantify islet survival after trans-
plantation, which demonstrated the potential of Nuclear Medicine Imaging in monitoring
islet survival with high sensitivity. Overall, these strategies required labeling of the
islets with radioactive probes prior to transplantation, if not the necessity to genetically 
modify the у-cells in order to express the radiotracer target receptor. Our study 
emphasizes on in vivo targeting of у-cells as an approach which allow visualizing islet 
transplants, without having the necessity to manipulate the islets in vitro, prior to 
transplantation (e.g. labeling with contrast agents and genetic modiﬁcation of the 
у-cells). While different transplantation sites can be used to validate у-cell radiotracers
(e.g. the liver, subcutaneous spaces, kidneys), we suggest the muscle as a convenient 
transplantation site that conﬁnes the islets in a small area, allowing easy visualization
and histological quantiﬁcation of BCM and the subsequent validation of radiotracers
in animal models.
Isolation of islets disrupts their vasculature and requires several weeks to restore 
completely after transplantation. As demonstrated in Chapter 3, exendin uptake was
evident in freshly isolated islets, as well as in the ﬁrst days after transplantation, 
suggesting the presence of GLP-1R in the ﬁrst days after transplantation. However,
delivery of 111In-exendin to the islets was optimal and reproducible 4 weeks after 
transplantation, when islet vasculature was completely restored. Consequently, 
quantiﬁcation of BCM was possible in 4-week old islet grafts, evidenced by the linear 
correlation between tracer accumulation in the graft and insulin volume (Chapter 4).
After determination of the optimal time-point for accurate quantiﬁcation of BCM in
islet transplants, in Chapter 5 we examined the effect of hyperglycemia on the 
accumulation of 111In-exendin in the у-cells. Our data indicated hyperglycemia decreases
tracer accumulation in the islets. Most importantly, re-establishing normoglycemia 
subsequent to a period of hyperglycemia allowed to restore the uptake of 111In-exendin
by the islets, suggesting that normalized blood glucose levels should be achieved 
prior to SPECT imaging, in order to monitor BCM in a reliable manner.
In Chapter 6, We have determined OPT as an accurate and easy method to 
validate exendin-based quantiﬁcation of BCM in animal models. Excellent linear correlation
between 111In-exendin uptake and insulin volume was achieved by SPECT-OPT, when 
compared to SPECT followed by histology, demonstrating that this new method may be 
more accurate in evaluating the performance of у-cell radiotracers during future studies.
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In dit proefschrift wordt het onderzoek beschreven om de eilandjes van Langerhans
in vivo zichtbaar te maken door middel van targeting van de glucagon-like peptide-1
receptor. Op deze manier wordt het mogelijk om de hoeveelheid overlevende 
eilandjes van Langerhans na transplantatie, een experimentele behandeling voor
diabetes type 1, te bepalen. In Hoofdstuk 2 wordt een overzicht gegeven van het
onderzoek om getransplanteerde eilandjes van Langerhans zichtbaar te maken met 
behulp van radionuclide beeldvorming. Bovendien wordt een overzicht gegevens
van de diermodellen die beschikbaar zijn om nieuwe radiotracers voor targeting van 
beta cellen (in de eilandjes van Langerhans) te valideren. Het laatste decennium zijn
er verschillende technieken gebruikt om eilandjes van Langerhans te visualiseren.
Een voorbeeld van deze methodes is het preïncuberen van de eilandjes met de 
radiotracer voordat de eilandjes getransplanteerd worden. Een ander voorbeeld is
het genetisch manipuleren van de eilandjes van Langerhans, zodat ze een eiwit tot 
expressie brengen die gebruikt kan worden voor targeting met een bekende 
radiotracer. Het nadeel van deze technieken is dat manipulatie van de eilandjes van
Langerhans voor de transplantatie noodzakelijk is. Het onderzoek beschreven in dit
proefschrift richt zich op een methode waarbij gebruikt wordt gemaakt van targeting 
van een receptor die al van nature op de beta cellen tot expressie komt. Deze 
methode maakt directe targeting van de beta cellen mogelijk, zonder dat de eilandjes 
vooraf gemanipuleerd hoeven te worden.
Verschillende locaties voor de transplantatie van eilandjes van Langerhans in 
diermodellen zijn beschreven, bijvoorbeeld in de lever, nier of onderhuids. Voor onze
studies hebben we gebruik gemaakt van transplantatie in de spier, waarbij de
eilandjes van Langerhans dicht bij elkaar in een klein gebied zitten. Dit maakt het 
makkelijk om de hoeveelheid eilandjes met behulp van histologische technieken te 
bepalen. Bovendien is het met dit model eenvoudig om het transplantaat zichtbaar te 
maken met radionuclide beeldvorming.
Na de isolatie procedure van de eilandjes van Langerhans uit de alvleesklier en 
de transplantatie procedure is het bloedvat netwerk van de eilandjes verloren gegaan.
Voor een goede overleving en functie van de getransplanteerde eilandjes is het
noodzakelijk dat dit bloedvat netwerk weer hersteld wordt. Voorgaande studies 
hebben aangetoond dat het 4 tot 6 weken duurt voor het bloedvat netwerk weer 
volledig hersteld is, afhankelijk van de locatie van transplantatie. De afwezigheid van
bloedvaten kan invloed hebben op de opname van de radiotracer die gebruikt wordt
in onze studies: exendin. In Hoofstuk 3 hebben we onderzocht wat het optimale 
tijdpunt is voor het afbeelden van getransplanteerde eilandjes. Direct na isolatie en 
de eerste dagen na transplantatie was er opname van radiogelabeld exendin te zien, 
wat suggereert dat de GLP-1R aanwezig is. De opname van radiogelabeld exendin in
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het transplantaat nam met de tijd toe en was stabiel na vier weken na transplantatie.
De stabilisering van de opname was in lijn met de herstellen van het bloedvat netwerk, 
wat ook na 4 weken niet meer toe nam. In Hoofdstuk 4 is aangetoond dat de hoeveel-
heid eilandjes van Langerhans in het transplantaat een lineaire correlatie heeft met
de hoeveelheid opname van radiogelabeld exendin. Deze resultaten tonen aan dat 
het mogelijk is om de hoeveelheid eilandjes van Langerhans te bepalen met behulp
van een exendin scan.
Nadat het optimale tijdpunt voor een exendin scan en de correlatie tussen de
hoeveelheid eilandjes en opname van radiolgelabeld exendin bepaald was hebben 
we het effect van hoge bloedglucose waarden op de opname van radiogelabeld 
exendin in de eilandjes van Langerhans bepaald in Hoofdstuk 5. We hebben 
aangetoond dat muizen (getransplanteerd met eilandjes van Langerhans) die hoge 
bloedglucose waarden hadden, minder opname van radiogelabeld exendin in de
eilandjes van Langerhans hadden. Dit effect was omkeerbaar: nadat de muizen weer
normale bloedglucose waarden hadden was de opname van radiogelabeld exendin 
in de eilandjes vergelijkbaar met de opname in gezonde muizen die gedurende het
gehele experiment normale bloedglucose waarden hadden.
In Hoofdstuk 6 hebben we een nieuwe methode om de hoeveelheid beta cellen 
te meten in alvleesklier weefsel vergeleken met de traditionele histologische methode.
De 3-dimensionale techniek Optical Projection Tomography (OPT) maakt het mogelijk om
de beta cellen in de gehele alvleesklier van een zichtbaar te maken en te kwantiﬁceren. 
Met de traditionele histologische methode is het alleen mogelijk om op 2-dimensionale
doorsnedes van het weefsel de hoeveelheid te bepalen. We hebben aangetoond dat
het meten van de hoeveelheid beta cellen met OPT een snelle, betrouwbare en 
accurate methode is voor het meten van de beta cellen en dat deze methode in de 
toekomst gebruikt kan worden voor het karakteriseren van beta cel tracers.
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